0001437749-23-031136.txt : 20231109 0001437749-23-031136.hdr.sgml : 20231109 20231109120027 ACCESSION NUMBER: 0001437749-23-031136 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OCULUS VISIONTECH INC. CENTRAL INDEX KEY: 0001107280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061576391 STATE OF INCORPORATION: WY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-29651 FILM NUMBER: 231391274 BUSINESS ADDRESS: STREET 1: 837 WEST HASTINGS STREET STREET 2: SUITE 507 CITY: VANCOUVER STATE: A1 ZIP: V6C 3N6 BUSINESS PHONE: 6046851017 MAIL ADDRESS: STREET 1: 837 WEST HASTINGS STREET STREET 2: SUITE 507 CITY: VANCOUVER STATE: A1 ZIP: V6C 3N6 FORMER COMPANY: FORMER CONFORMED NAME: OCULUS VISION TECH INC. DATE OF NAME CHANGE: 20120201 FORMER COMPANY: FORMER CONFORMED NAME: USA VIDEO INTERACTIVE CORP DATE OF NAME CHANGE: 20000217 10-Q 1 ovtz20230930_10q.htm FORM 10-Q ovtz20230930_10q.htm
0001107280 OCULUS VISIONTECH INC. false --12-31 Q3 2023 0 0 250,000,000 250,000,000 0 0 0 0 500,000,000 500,000,000 91,422,569 91,422,569 91,422,569 91,422,569 0.00 0 500,000,000 91,422,569 0 0 December 21, 2023 January 29, 2024 June 10, 2024 October 14, 2024 January 31, 2025 0.001 No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per ComplyTrust Inc.’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control. 00011072802023-01-012023-09-30 xbrli:shares 00011072802023-11-09 thunderdome:item iso4217:USD 00011072802023-09-30 00011072802022-12-31 0001107280us-gaap:NonrelatedPartyMember2023-09-30 0001107280us-gaap:NonrelatedPartyMember2022-12-31 0001107280us-gaap:RelatedPartyMember2023-09-30 0001107280us-gaap:RelatedPartyMember2022-12-31 iso4217:USDxbrli:shares 00011072802023-07-012023-09-30 00011072802022-07-012022-09-30 00011072802022-01-012022-09-30 0001107280us-gaap:CommonStockMember2022-12-31 0001107280us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001107280us-gaap:RetainedEarningsMember2022-12-31 0001107280us-gaap:CommonStockMember2023-01-012023-09-30 0001107280us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-30 0001107280us-gaap:RetainedEarningsMember2023-01-012023-09-30 0001107280us-gaap:CommonStockMember2023-09-30 0001107280us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 0001107280us-gaap:RetainedEarningsMember2023-09-30 0001107280us-gaap:CommonStockMember2023-06-30 0001107280us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 0001107280us-gaap:RetainedEarningsMember2023-06-30 00011072802023-06-30 0001107280us-gaap:CommonStockMember2023-07-012023-09-30 0001107280us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0001107280us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001107280us-gaap:CommonStockMember2021-12-31 0001107280us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001107280ovtz:CommitmentToIssueSharesMember2021-12-31 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0001107280us-gaap:RetainedEarningsMember2021-12-31 00011072802021-12-31 0001107280us-gaap:CommonStockMember2022-01-012022-09-30 0001107280us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-30 0001107280ovtz:CommitmentToIssueSharesMember2022-01-012022-09-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-30 0001107280us-gaap:RetainedEarningsMember2022-01-012022-09-30 0001107280us-gaap:CommonStockMember2022-09-30 0001107280us-gaap:AdditionalPaidInCapitalMember2022-09-30 0001107280ovtz:CommitmentToIssueSharesMember2022-09-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-30 0001107280us-gaap:RetainedEarningsMember2022-09-30 00011072802022-09-30 0001107280us-gaap:CommonStockMember2022-06-30 0001107280us-gaap:AdditionalPaidInCapitalMember2022-06-30 0001107280ovtz:CommitmentToIssueSharesMember2022-06-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-30 0001107280us-gaap:RetainedEarningsMember2022-06-30 00011072802022-06-30 0001107280us-gaap:CommonStockMember2022-07-012022-09-30 0001107280us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-30 0001107280ovtz:CommitmentToIssueSharesMember2022-07-012022-09-30 0001107280us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-30 0001107280us-gaap:RetainedEarningsMember2022-07-012022-09-30 00011072802022-01-012022-12-31 xbrli:pure 0001107280ovtz:ComplytrustIncMember2023-09-30 0001107280ovtz:ComplytrustIncMember2022-12-31 0001107280us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0001107280us-gaap:EmployeeStockOptionMember2022-01-012022-09-30 0001107280us-gaap:WarrantMember2023-01-012023-09-30 0001107280us-gaap:WarrantMember2022-01-012022-09-30 0001107280ovtz:RollingStockOptionPlanMember2023-09-30 0001107280ovtz:RollingStockOptionPlanMemberovtz:VestingEverySixMonthsMember2023-01-012023-09-30 0001107280ovtz:RollingStockOptionPlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-09-30 0001107280ovtz:RollingStockOptionPlanMember2023-01-012023-09-30 0001107280ovtz:RollingStockOptionPlanMember2022-01-012022-09-30 0001107280ovtz:RangeTwoMember2023-09-30 0001107280ovtz:RangeTwoMember2023-01-012023-09-30 utr:Y 0001107280ovtz:RangeThreeMember2023-09-30 0001107280ovtz:RangeThreeMember2023-01-012023-09-30 0001107280ovtz:RangeFourMember2023-09-30 0001107280ovtz:RangeFourMember2023-01-012023-09-30 0001107280ovtz:RangeFiveMember2023-09-30 0001107280ovtz:RangeFiveMember2023-01-012023-09-30 0001107280ovtz:RangeSixMember2023-09-30 0001107280ovtz:RangeSixMember2023-01-012023-09-30 0001107280ovtz:WarrantsExpiringOnJune42025Member2023-09-30 0001107280ovtz:WarrantsExpiringOnJune42025Member2023-01-012023-09-30 0001107280ovtz:ConsultingFeesMember2023-01-012023-09-30 0001107280ovtz:ConsultingFeesMember2022-01-012022-09-30 0001107280us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-30 0001107280us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-30 0001107280ovtz:SharebasedCompensationMember2023-01-012023-09-30 0001107280ovtz:SharebasedCompensationMember2022-01-012022-09-30 0001107280ovtz:ConsultingFeesMember2023-01-012023-09-30 0001107280ovtz:ConsultingFeesMember2022-01-012022-09-30 iso4217:CAD 0001107280ovtz:VancouverCAOperatingLeaseMember2023-01-012023-09-30 0001107280ovtz:VancouverCAOperatingLeaseMember2022-01-012022-09-30
 
 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission File Number: 0-29651

 

pic1.jpg

 

OCULUS VISIONTECH INC.

(Exact name of registrant as specified in its charter)

 

Wyoming

06-1576391

(State or Other Jurisdiction of

(I.R.S. Employer

Incorporation or Organization)

Identification No.)

 

Suite 507 - 837 West Hastings Street, Vancouver, BC, Canada, V6C 3N6

(Address of principal executive offices) (Zip code)

 

(604) 685-1017

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes   ☑      No   ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

 

Yes    ☑      No ☐

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” ‘‘accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large, accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

  

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

 

Yes          No ☑

 

As at November 9th, 2023, there were 91,422,569 shares of the registrant’s common stock outstanding

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol(s)

Name of each exchange on which registered

Common

  

Common stock - no par value

OVTZ

Over The Counter Bulletin Board

Preferred stock - no par value

N/A

N/A

Common stock - no par value

OVT

TSX Venture Exchange

Common stock - no par value

USF1

Frankfurt Stock Exchange

 

 

 

TABLE OF CONTENTS

 

PART I  FINANCIAL INFORMATION

   

Forward Looking Statements

4

Item 1.  

 

Financial Statements

6

   

Condensed Interim Consolidated Balance Sheets

6

 

(A)

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss

7

 

(B)

Condensed Interim Consolidated Statements of Stockholders Equity

8

 

(C)

Condensed Interim Consolidated Statements of Cash Flows

10

 

(D)

Notes to Condensed Interim Consolidated Financial Statements

11

Item 2.  

(E)

Managements Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

 

Controls and Procedures

23

       
   

PART II  OTHER INFORMATION

 
       

Item 1.  

 

Legal Proceedings

24

Item 1A.

 

Risk Factors

24

Item 2.     

 

Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3.

 

Defaults Upon Senior Securities

24

Item 4.

 

Mine Safety Disclosure

24

Item 5.

 

Other Information

24

Item 6.

 

Exhibits

24

 

 

 

FORWARD LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for the purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify these statements by forward-looking words such as “plan”, “may”, “will”, “expect”, “intend”, “anticipate”, believe”, “estimate” and “continue” or similar words. Forward-looking statements are statements that are not historical facts, and include, but are not limited to:

 

statements regarding our products and services, including:

 

o

our digital watermarking technology and Cloud-based document protection system;

 

o

our data privacy and data protection services and solutions; our technology, our cash needs, including our ability to fund our future capital expenditures and working capital requirements;

 

o

our expectations regarding competition and growth in our sector; the future sources and availability of additional funding; and

 

o

the effect of funding arrangements on projects and products.

 

You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, except as required by law.

 

Forward-looking statements are based on current expectations about future events affecting the Company and are subject to uncertainties and factors that affect all business operating in a global market as well as matters specific to the Company. These uncertainties and factors are difficult to predict, and many of them are beyond the Company’s control. Factors to consider when evaluating these forward-looking statements include, but are not limited to:

 

 

the impact of pandemics;

 

the Company’s limited operating history makes it difficult to evaluate its business and prospects;

 

the Company has incurred substantial losses and expects to incur losses in the future and may never achieve profitability;

 

if the Company is unable to obtain substantial additional financing, it may not be able to remain in business;

 

the Company’s operating results in future periods are expected to be subject to significant fluctuations, which would likely affect the trading price of the Company’s common shares;

 

the data privacy and data protection markets are highly competitive, and the Company’s failure to successfully compete will limit its ability to attain, retain and increase its market share;

 

the document protection market is highly competitive, and the Company’s failure to compete successfully would limit its ability to retain and increase its market share;

 

the video digital watermarking business is highly competitive, and the Company’s failure to compete successfully would limit its ability to retain and increase its market share;

 

the Company is subject to rapid technological change, which could render its products and services obsolete;

 

the Company is dependent upon vendors and other third-party service providers and will be competing with some of these companies;

 

the Company’s services are technically complex, and it may not be able to prevent defects that could decrease their market acceptance, result in product liability, or harm its reputation;

 

any loss of the Company’s personnel or inability to acquire new personnel could harm its business;

 

a failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have material adverse effect on the Company’s business and operating results and shareholders could lose confidence in the Company’s financial reporting;

 

the Company does not currently have any paying customers;

 

the Company’s business may suffer if it cannot protect its intellectual property;

 

the Company’s products may infringe the intellectual property rights of others, causing the Company to incur significant costs or prevent us from licensing its products;

 

the Company’s success depends on the continued growth in demand for e-business applications;

 

government regulation and legal uncertainties could add additional costs and risks to doing business on the Internet;

 

the Company’s share price has been and could be highly volatile, which could result in substantial losses to investors;

 

the Company has not paid cash dividends in the past and does not expect to pay cash dividends in the foreseeable future.

 

 

Any return on investment may be limited to the value of the Company’s common shares;

 

securities analysts may not initiate coverage or continue to cover the Company’s common shares, and this may have a negative impact on its market price;

 

anti-takeover provisions in our charter documents could prevent or delay a change in control of the Company;

 

the Company intends to issue additional equity securities, which may dilute the interests of current shareholders or carry rights or preferences senior to the common shares;

 

the exercise of options and warrants and other issuances of common shares or securities convertible into or exercisable for common shares will dilute the ownership interest of the Company’s current shareholders and may adversely affect the future market price of the Company’s common shares;

 

limited liability of executive officers and directors may discourage shareholders from bringing a lawsuit against them;

 

requirements of the SEC with regard to low-priced “penny stocks” may adversely affect the ability of shareholders to sell their shares in the secondary market;

 

the Company does not anticipate paying dividends to shareholders in the foreseeable future;

 

the Company may be exposed to adverse currency exchange rate fluctuations, which could harm the Company’s financial results and cash flows;

 

service outages and disruption of the Company’s infrastructure may harm the Company and adversely impact business operations and injure reputation;

 

security vulnerabilities in the Company’s products and services or any breach of the Company’s security measures may injure its reputation and disrupt the Company’s business;

 

the financial reporting obligations of being a public company in the United States are expensive, time consuming, and may place significant demands on the Company’s management; and

 

the Company’s failure to manage or adequately address any one or more of these risks could result in the business suffering a material adverse effect.

 

The Company believes the items outlined above are important factors that could cause estimates included in its financial statements to differ materially from the actual results and those expressed in a forward-looking statement made in this report or elsewhere by the Company or on its behalf. The Company has discussed these factors in more detail under “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and other periodic reports filed with the United States Securities and Exchange Commission (“SEC”). Accordingly, to the extent that this quarterly report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of the Company, please be advised that the Company’s actual financial condition, operating results and business performance may differ materially from that projected or estimated by the Company in forward-looking statements. We do not intend to update our description of important factors each time a potential important factor arises, except as required by applicable securities laws and regulations. We advise our shareholders that they should (i) be aware that factors not referred to above could affect the accuracy of the Company’s forward-looking statements and (ii) use caution when considering the Company’s forward-looking statements.

 

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(Stated in US Dollars)

(Unaudited)

 

  

September 30,

2023

  

December 31,

2022

 
         
         

ASSETS

        
         

Current Assets:

        

Cash and cash equivalents

 $239,682  $687,602 

Prepaid expenses and other current assets (Note 4)

  7,447   30,238 

Total Assets

 $247,129  $717,840 
         

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)

        
         

Current Liabilities:

        

Accounts payable and accrued liabilities (Note 5)

 $103,226  $133,796 

Accounts payable and accrued liabilities - related parties

  150,110   168,627 

Total current liabilities

  253,336   302,423 
         

Stockholders' Equity (Deficiency):

        

Preferred stock - no par value; authorized 250,000,000 shares, none issued

        

Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569

  46,850,710   46,850,710 

Additional paid in capital

  1,470,933   1,394,997 

Accumulated other comprehensive loss

  (36,598)  (34,856)

Accumulated deficit

  (48,291,252)  (47,795,434)

Stockholders' equity (deficiency)

  (6,207)  415,417 

Total Liabilities and Stockholders' Equity (Deficiency)

 $247,129  $717,840 

 

 

SEE ACCOMPANYING NOTES

 

 

 

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Stated in US Dollars)

(Unaudited)

 

   

For the three months ended

September 30,

   

For the nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Expenses:

                               

Consulting (Note 11)

  $ 45,000     $ 45,000     $ 135,000     $ 90,000  

Research and development (Note 10)

    4,624       283,269       93,561       912,892  

Selling, general and administrative (Notes 9 and 11)

    79,049       116,163       200,696       310,987  

Stock-based compensation (Notes 7 and 11)

    14,923       80,267       75,936       336,107  
                                 

Loss from operations

    (143,596 )     (524,699 )     (505,193 )     (1,649,986 )

Interest income

    3,089       -       9,375       -  
                                 

Net loss

    (140,507 )     (524,699 )     (495,818 )     (1,649,986 )
                                 

Other comprehensive loss

                               

Currency translation differences

    (1,878 )     (22,525 )     (1,742 )     (46,409 )
                                 

Total comprehensive loss

  $ (142,385 )   $ (547,224 )   $ (497,560 )   $ (1,696,395 )
                                 

Net loss per share - basic and diluted

  $ (0.00 )   $ (0.01 )   $ (0.01 )   $ (0.02 )
                                 

Weighted average number of common shares outstanding – basic and diluted

    91,422,569       91,422,569       91,422,569       91,422,569  

 

 

SEE ACCOMPANYING NOTES

 

 

 

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY)

(Stated in US Dollars)

(Unaudited)

 

Nine Month Period Ended September 30, 2023

 
                                                 
   

Common

Shares

   

Amount

   

Additional

Paid in Capital

   

Accumulated

Other Comprehensive Loss

   

Accumulated Deficit

   

Stockholders Equity

(Deficiency)

 
                                                 

Balance at December 31, 2022

    91,422,569     $ 46,850,710     $ 1,394,997     $ (34,856 )   $ (47,795,434 )   $ 415,417  
                                                 

Share-based compensation

    -       -       75,936       -       -       75,936  

Currency translation differences

    -       -       -       (1,742 )     -       (1,742 )

Net loss

    -       -       -       -       (495,818 )     (495,818 )
                                                 

Balance at September 30, 2023

    91,422,569     $ 46,850,710     $ 1,470,933     $ (36,598 )   $ (48,291,252 )   $ (6,207 )

 

Three Month Period Ended September 30, 2023

 
                                                 
   

Common

Shares

   

Amount

   

Additional

Paid in Capital

   

Accumulated

Other Comprehensive Loss

   

Accumulated Deficit

   

Stockholders Equity

(Deficiency)

 
                                                 

Balance at June 30, 2023

    91,422,569     $ 46,850,710     $ 1,456,010     $ (34,720 )   $ (48,150,745 )   $ 121,255  
                                                 

Share-based compensation

    -       -       14,923       -       -       14,923  

Currency translation differences

    -       -       -       (1,878 )     -       (1,878 )

Net loss

    -       -       -       -       (140,507 )     (140,507 )
                                                 

Balance at September 30, 2023

    91,422,569     $ 46,850,710     $ 1,470,933     $ (36,598 )   $ (48,291,252 )   $ (6,207 )

 

 

Nine Month Period Ended September 30, 2022

 
                                                         
   

Common Shares

   

Amount

   

Additional

Paid in Capital

   

Commitment to Issue Shares

   

Accumulated Other Comprehensive Income (Loss)

   

Accumulated Deficit

   

Stockholders Equity

 
                                                         

Balance at December 31, 2021

    91,422,569     $ 46,850,710     $ 998,477     $ 414,128     $ 6,190     $ (46,145,845 )   $ 2,123,660  
                                                         

Share-based compensation

    -       -       336,107       -       -       -       336,107  

Currency translation differences

    -       -       -       -       (46,409 )     -       (46,409 )

Net loss

    -       -       -       -       -       (1,649,986 )     (1,649,986 )
                                                         

Balance at September 30, 2022

    91,422,569     $ 46,850,710     $ 1,334,584     $ 414,128     $ (40,219 )   $ (47,795,831 )   $ 763,372  

 

Three Month Period Ended September 30, 2022

 
                                                         
   

Common Shares

   

Amount

   

Additional Paid in Capital

   

Commitment to Issue Shares

   

Accumulated Other Comprehensive Income (Loss)

   

Accumulated Deficit

   

Stockholders Equity

 
                                                         

Balance at June 30, 2022

    91,422,569     $ 46,850,710     $ 1,254,317     $ 414,128     $ (17,694 )   $ (47,271,132 )   $ 1,230,329  
                                                         

Share-based compensation

    -       -       80,267       -       -       -       80,267  

Currency translation differences

    -       -       -       -       (22,525 )     -       (22,525 )

Net loss

    -       -       -       -       -       (524,699 )     (524,699 )
                                                         

Balance at September 30, 2022

    91,422,569     $ 46,850,710     $ 1,334,584     $ 414,128     $ (40,219 )   $ (47,795,831 )   $ 763,372  

 

 

SEE ACCOMPANYING NOTES

 

 

 
 

OCULUS VISIONTECH INC. AND SUBSIDIARY

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Stated in US Dollars)

(Unaudited)

 


 

 

Nine months ended September 30,

 

2023

   

2022

 
                 

Cash flows from operating activities:

               

Net loss

  $ (495,818 )   $ (1,649,986 )

Add back non-cash share-based compensation

    75,936       336,107  

Adjustments to reconcile net loss to net cash used in operating activities:

               

Changes in operating assets and liabilities:

               

Decrease in prepaid expenses and other current assets

    22,791       14,678  

Increase (decrease) in accounts payable and accrued liabilities

    (30,570 )     53,125  

Increase (decrease) in accounts payable and accrued liabilities – related parties

    (18,517 )     104,945  

Net cash used in operating activities

    (446,178 )     (1,141,131 )
                 

Effect of foreign currency translation

    (1,742 )     (47,363 )
                 

Net decrease in cash and cash equivalents

    (447,920 )     (1,188,494 )

Cash and cash equivalents at beginning of period

    687,602       2,208,451  

Cash and cash equivalents at end of period

  $ 239,682     $ 1,019,957  
                 
                 

Supplemental disclosures of cash flow information:

               
                 

Cash paid during the period for interest

  $ -     $ -  

Cash paid during the period for income taxes

  $ -     $ -  

 

There were no non-cash financing or investing activities for the periods presented.

 

 

SEE ACCOMPANYING NOTES

 

10

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

1.

BASIS OF PRESENTATION AND BUSINESS

 

Oculus VisionTech, Inc. (the "Company") is a development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Substantially all of the Company's assets and substantially all its operations are located and conducted in the United States and Canada.

 

The unaudited condensed consolidated financial statements and notes herein should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed interim consolidated financial statements included herein have been prepared by the Company without audit, pursuant to the roles and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the SEC’s rules and regulations. Although management believes that the disclosures are adequate and make the information presented not misleading. In the opinion of management, all adjustments, which are of a normal and recurring nature (except as otherwise noted), that are necessary to present fairly the Company’s financial position as of September 30, 2023 and December 31, 2022, and its results of operation for the nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022

 

2.

GOING CONCERN

 

These condensed interim consolidated financial statements are prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses from inception and does not currently have the financial resources to sustain operations in the long-term. As shown in the financial statements, the Company has incurred a loss of $495,818 for the nine months ended September 30, 2023 and, in addition the Company incurred losses of $1,649,589 for the year ended December 31, 2022. As of September 30, 2023, the Company had an accumulated deficit of $48,291,252 and working capital deficiency of $6,207. As a result of the Company’s current financial position and challenging access to capital, there can be no assurance that the Company will be able raise additional funds in the future, in which case the Company will be unable to meet its financial obligations. These material uncertainties raise substantial doubt upon the Company’s ability to continue as a going concern. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. The Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations as they come due which management believes it will be able to do. To date, the Company has funded operations primarily through the issuance of common stock and warrants to outside investors and the Company’s management. The Company believes that its operations will generate additional funds and that additional funding from outside investors and the Company’s management will continue to be available to the Company when needed.

 

3.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of consolidation

 

These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On November 14, 2023, the Board approved the condensed interim consolidated financial statements dated September 30, 2023.

 

These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.

 

Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.

 

11

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

The controlled entities are listed in the following table:

 

Name of Subsidiary

Country of

Incorporation

 

Ownership

Interest at

September 30,

2023

  

Ownership

Interest at

December 31,

2022

 

Principal Activity

           

ComplyTrust Inc.

US/Delaware

  100

%

  100

%

Software Development

 

Significant judgments, estimates and assumptions

 

The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.

 

The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following:

 

Significant judgments

 

the determination of functional currencies

 

share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.

 

Cash and cash equivalents

 

Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

 

Impairment of long-lived assets and long-lived assets to be disposed of

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.

 

Research and development

 

Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at September 30, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.

 

12

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

Intangible assets

 

Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.

 

The useful lives of intangible assets are assessed as either finite or indefinite.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.

 

Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.

 

Income taxes

 

The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

 

Net loss per share

 

Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended September 30, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 1,815,000 (2022: 5,415,000) stock options and 12,500,000 (2022: 17,400,000) warrants were excluded from the calculation.

 

Stock-based compensation

 

The Company follows the provisions of the Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.

 

The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.

 

13

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

Functional currency

 

The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.

 

In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.

 

Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.

 

Recently issued accounting pronouncements

 

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

 

4.

PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consist of the following:

 

   

September 30,

   

December 31,

 
   

2023

   

2022

 
                 

Prepaid expenses

  $ 3,035     $ 28,028  

Tax Receivable – Canadian GST

    4,412       2,210  
    $ 7,447     $ 30,238  
 

5.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities consist of the following:

 

   

September 30,

2023

   

December 31,

2022

 
                 

Accounts payable

  $ 85,532     $ 81,927  

Accrued fees and liabilities

    17,694       51,869  
    $ 103,226     $ 133,796  

 

14

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

6.

COMMON STOCK 

 

The Company has no par value common stock with 500,000,000 authorized shares and 91,422,569 outstanding on September 30, 2023 and December 31, 2022.

 

The Company has authorized the issuance of 250,000,000 non-voting preferred shares without par value, none issued.

 

As of September 30, 2023, there were Nil common shares held in escrow.

 

7.

STOCK OPTIONS

 

During the period ended September 30, 2023 and year ended December 31, 2022, the Company had a Rolling Stock Option Plan. Up to 10% of the Company’s issued and outstanding common shares may be reserved for granting of stock options. All of the options granted vest 20% every six months.

 

However, all options will be considered vested if one of the following criteria are met by the Company:

 

 i.Meeting sales forecasts:
  -The greater of either the 20% vesting every six months or based on a pro rata percentage of revenue earned by the Company’s subsidiary.
    
 ii.the listing of the Company on any national securities exchange.
    
 iii.a Change of Control Event.

 

During the period ended September 30, 2023, the Company did not grant any stock options and recorded $75,936 (2022: $336,107) of share-based compensation for vested portion that were previously granted.

 

The changes in options are as follows:

 

  

Number of

options

  

Weighted

average

exercise price

  

Aggregate

Intrinsic Value

 

Options outstanding, December 31, 2021

  5,315,000  $0.49  $- 

Granted

  100,000   0.80   - 

Options outstanding, December 31, 2022

  5,415,000  $0.50  $- 

Expired

  (3,600,000)  0.35   - 

Options outstanding, September 30, 2023

  1,815,000  $0.80  $- 

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at September 30, 2023.

 

15

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

Details of options outstanding as at September 30, 2023 are as follows:

 

Exercise price

(CAD)

  

Number of

options

outstanding

 

Expiry date

 

Number of options

exercisable

  

Remaining

contractual life (years)

 
                
$0.450   250,000 

December 21, 2023

  250,000   0.22 
$1.200   500,000 

January 29, 2024

  500,000   0.33 
$0.800   375,000 

June 10, 2024

  300,000   0.70 
$0.600   590,000 

October 14, 2024

  354,000   1.04 
$0.800   100,000 

January 31, 2025

  40,000   1.34 
                
     1,815,000    1,444,000     

 

 

8.

WARRANTS

 

The changes in warrants are as follows:

 

   

Number of

warrants

   

Weighted

average

exercise price

 

Warrants outstanding, December 31, 2021 and 2022

    17,400,000     $ 0.28  

Expired

    (4,900,000 )   $ 1.00  

Warrants outstanding, September 30, 2023

    12,500,000     $ 0.001  

 

Details of warrants outstanding as at September 30, 2023 are as follows:

 

Exercise price

       

Number of

warrants

outstanding

 

Expiry date

 

Number of

warrants

exercisable

   

Remaining

contractual life

(years)

 
                                   
$ 0.001 (1)  

(USA)

    12,500,000  

June 4, 2025

    -       1.68  
                                   
              12,500,000         -          

 

 

(1)

No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per ComplyTrust Inc.’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.

 

16

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

9.

SELLING, GENERAL AND ADMINISTRATIVE

 

The breakdown of selling, general and administrative for the period ended September 30, 2023 and 2022 is as follows:

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Filing and regulatory fees

  $ 8,514     $ 5,789     $ 26,557     $ 34,280  

Marketing

    -       19,359       -       73,053  

Professional fees

    13,614       20,733       39,722       67,882  

Rent

    10,936       10,249       32,587       28,807  

Office and administration

    45,985       60,033       101,830       106,963  
                                 
    $ 79,049     $ 116,163     $ 200,696     $ 310,987  
 

10.

RESEARCH AND DEVELOPMENT

 

The breakdown of research and development for the period ended September 30, 2023 and 2022 is as follows:

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Project management

  $ -     $ -     $ -     $ 11,990  

Software development

    4,624       203,687       59,123       677,035  

Business development

    -       33,435       3,952       99,636  

Payroll

    -       46,147       30,486       124,231  
                                 
    $ 4,624     $ 283,269     $ 93,561     $ 912,892  
 

11.

RELATED PARTIES

 

Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

 

The Company defines its key management as the Board of Directors, Chief Executive Officer, President, and Chief Financial Officer. Remuneration of directors and key management personnel of the Company for the period ended September 30, 2023 and 2022 was as follows:

 

       
  

2023

  

2022

 
         

Consulting

 $135,000  $90,000 

Selling general and administrative

  79,913   65,742 

Share-based compensation to directors and officers

  1,442   40,761 
  $216,355  $196,503 

 

The Company for the period ended September 30, 2023 and 2022 reimbursed a related party $79,913 and $65,742, respectively, for selling, general and administrative expenses paid on behalf of the Company. The Company incurred $135,000 (2022 - $90,000) of consulting fees accrued to a company controlled by a director of the Company for the period ended September 30, 2023 and 2022.

 

17

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

The Company also recorded share-based compensation of $1,442 (2022 - $40,761) for options vested to related parties during the period ended September 30, 2023 and 2022.

 

12.

FINANCIAL INSTRUMENTS AND RISKS

 

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are described below.

 

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

 

Fair value of financial instruments

 

The Company has various financial instruments including cash and cash equivalents, accounts payable and accrued liabilities, and accounts payable and accrued liabilities – related parties. The carrying values of accounts payable and accrued liabilities and accounts payable and accrued liabilities – related parties approximate their fair values due to the short-term nature of these financial instruments.

 

Cash and cash equivalents is carried at a level 1 fair value measurement.

 

The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:

 

Credit risk

The Company is exposed to credit risk only with respect to uncertainties as to timing and amount of collectability of receivables. The Company believes its credit risk is low because receivables is comprised of goods and services tax (GST) which is recoverable from the governing body in Canada. Management does not believe the receivables are impaired. The Company doesn’t believe there is significant credit risk associated with cash as these amounts are held with major Canadian banks.

 

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2023, the Company had a cash and cash equivalents balance of $239,682 ( December 31, 2022 – $687,602) to settle current liabilities of $253,336 ( December 31, 2022 – $302,423). All of the Company’s financial liabilities have contractual maturities of 30 days or due on demand and are subject to normal trade terms.

 

Interest rate risk

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize such a loss is limited as it does not have any significant interest-bearing financial instruments.

 

Foreign currency risk

As at September 30, 2023 and December 31, 2022, the Company is exposed to foreign currency risk as certain monetary financial instruments are denominated in Canadian currency. The Company’s sensitivity analysis suggests that reasonably expected changes in the rates of exchange in the United States would change foreign exchange gain or loss by an insignificant amount.

 

13.

OPERATING LEASES

 

The Company has one operating lease with unrelated third parties for office space at Vancouver, Canada.

 

The lease at the Vancouver, Canada location is on a month-to-month basis with monthly rental payments of $3,950 (CND). For the period ended September 30, 2023 and 2022 rent expense was $31,066 and $27,288, respectively.

 

18

OCULUS VISIONTECH INC. AND SUBSIDIARY
NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2023 and 2022
(Stated in US Dollars)
(Unaudited)
 

14.

SEGMENTED INFORMATION

 

The Company currently operates in a single reportable operating segment. All of the Company’s assets and expenditures are located in Canada and the United States.

 
19
 

Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

FORWARD-LOOKING STATEMENTS AND SUPPLEMENTARY DATA

 

The following discussion should be read in conjunction with our condensed interim financial statements and other financial information appearing elsewhere in this quarterly report. In addition to historical information, the following discussion and other parts of this quarterly report contain forward-looking statements under applicable securities laws. You can identify these statements by forward-looking words such as “plan”, “may”, “will”, “expect”, “intend”, “anticipate”, believe”, “estimate” and “continue” or similar words. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, statements regarding our products and services, including our digital watermarking technology and Cloud-based document protection system, our data privacy and data protection services and solutions, our technology, our cash needs, including our ability to fund our future capital expenditures and working capital requirements, and our expectations regarding competition and growth in our sector, are forward looking statements, the future sources and availability of additional funding, and the effect of funding arrangements on projects and products. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, except as required by law.

 

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and other periodic reports filed with the United States Securities and Exchange Commission (“SEC”). Accordingly, to the extent that this quarterly report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of the Company, please be advised that the Company’s actual financial condition, operating results and business performance may differ materially from that projected or estimated by the Company in forward-looking statements.

 

OVERVIEW OF THE COMPANY

 

Oculus VisionTech Inc. (OVTZ) is a Canadian-based development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Headquartered in Vancouver, British Columbia, Canada, the company was originally founded by image processing experts and is operated by experienced leadership. Currently, OVTZ is expanding and investing in a suite of new data protection and data privacy security products that will revolutionize CCPA, GDPR, LGPD and other data privacy legislation compliance for both data subjects and data controllers worldwide. Our mission is innovation of viable software tools that enable intelligent automated solutions for public cloud customer services and needs specific to data privacy and data protection for individuals, organizations and their customers worldwide, through a vision of mutually trusted data compliance.

 

Our Forget-Me-Yes® data privacy product is a Software-as-a-Service (SaaS) platform developed to specifically address the global ‘Right-to-be-Forgotten’ (RtbF) and Right-of-Erase (RoE) legal components of Brazil’s LGPD, Europe’s GDPR, California Consumer Privacy Act (CCPA), Colorado Privacy Act (CPA) and Virginia CDPA data privacy regulatory compliance. An additional new data protection software tool, ComplyScan®, is being developed to address public cloud data governance compliance. Our legacy Cloud Document Protection System (Cloud-DPS) technology leveraged our digital watermarking technology to enable OVTZ to offer a SaaS-based document management platform for tamper-proof document authentication and protection. Historically, we have used our digital watermarking technology for streaming video content distribution based on embedded digital watermarking, as well as video-on-demand (VOD) systems, services and source-to-destination digital media delivery solutions that allow live or recorded digitized and compressed video to be transmitted through Internet, intranet, satellite or wireless connectivity.

 

We were incorporated on April 18, 1986, as "First Commercial Financial Group Inc." in the Province of Alberta, Canada. In 1989, our name was changed to "Micron Metals Canada Corp.", which purchased 100% of the outstanding shares of USA Video Inc., a Texas corporation, in order to focus on the digital media business. In 1995, we changed our name to "USA Video Interactive Corp." and continued out of the Province of Alberta into the State of Wyoming. At a shareholders meeting held on December 30, 2011, a resolution was passed to change our name to "Oculus VisionTech Inc." and to alter our share capital by way of a reverse stock split (share consolidation) on the basis of fifteen old common shares for one new common share. On January 25, 2012, we changed our name to "Oculus VisionTech Inc." In June 2020, OVTZ acquired OCL Technologies Inc. (OCL), a Delaware corporation data privacy software development startup based in San Diego, California. As a 100% wholly-owned subsidiary of OVTZ and to better align with customer and market focus, OCL has completed a corporate name change to ComplyTrust® Inc. (CTI) on January 21, 2021. All OCL references throughout this document are synonymous with the new name change, CTI.

 

 

Our executive and corporate headquarter offices are located at Suite 507, 837 West Hastings Street, Vancouver, British Columbia, Canada, V6C 3N6. Our telephone number is 1-800-684-0183 and our facsimile number is 604-685-5777. Our email address is contact@ovtz.com and our website is www.ovtz.com. Our common shares are listed for trading on the TSX Venture Exchange (TSX.V – OVT, OTCQB – OVTZ, FSE – USF1).

 

BUSINESS OBJECTIVES:

 

In this age of digital transformation, data monetization, IoT, and massive data migration to converged hyperscale, geo-disbursed Cloud infrastructure and workloads, data protection and data privacy have taken center stage. GDPR, LGPD, CCPA, and many other new international (Canada/PIPEDA, China/PIPL, India/DIA) and upcoming US Federal (ADPPA) and individual State data privacy regulations enable individuals and organizations the right to access and request deletion of all personal information for a given data subject. In our ever increasing Everything-as-a-Service world, OVTZ recognizes the need for global cloud-native data privacy and data protection solutions that are multi-cloud platform-ready and can augment both existing legacy and newer agile-driven architectures. OVTZ is building modular microservices-based software solutions and services for both hybrid on-premise and multi-cloud data management that incorporate automated malware, privacy and ransomware scanning, reporting and visualization.

 

Our new Forget-Me-Yes® (FMY) Software-as-a-Service (SaaS) data privacy solution is a secure, Zero-Knowledge platform providing a single-source capability of continuous ‘right-to-be-forgotten’ (RtbF) and ‘right-of-erase’ (RoE) privacy compliance by incorporating automated policy-driven re-query services that guarantees a Data Subject’s requested RtbF/RoE data remains ‘forgotten’ over the life of their FMY subscription. FMY incorporates hybrid encryption technology that ensures all User Interface, data-in-transit and data-at-rest remain secure and can only be accessed by the subscriber. With a cloud-native architecture, the FMY functionality can be utilized as either a complete turnkey SaaS subscription platform, or individually licensed for seamless integration with existing 3rd party applications and data privacy platforms.

 

Our new ComplyTrust® Software-as-a-Service Suite (CTSS) is a set of software tools specifically designed to address cloud-native data management and regulatory compliant data governance. CTSS will help to remove enterprise organizational barriers and blockers to further enable successful cloud migration and deployment that benefit the cloud infrastructure providers, enterprise organizations, and users collectively. CTSS helps to automate and visualize cloud compliance reporting across accounts, regions and services based on a variety of user-definable and data driven metrics. Development of the first CTSS product, a cloud-native data backup compliance reporting tool called ComplyScan® (CS), has commenced.

 

OVTZ had recognized that cloud-based, digital document security/protection products were a potentially viable business opportunity for the Company that allowed us to apply our proprietary real-time digital video watermarking technology, originally developed for studios and networks in the entertainment industry, to the digital document security/protection market. Cloud-DPS secures and protects digital documents (including text documents, photos, blueprints, etc.) from any modification, and/or attempted forgery by imperceptibly watermarking documents, using real-time image processing and watermarking algorithms, embedded into a secured/protected copy of a document. This authentication and verification process ensures the integrity of the original digital document.

 

Our near-term business objectives for the above:

 

1.

Patent and license new technology developed within the corporate research and development program;

 

2.

Demonstrate proof of concept on selected commercial projects with our Forget-Me-Yes® (FMY) data privacy Software-as-a-Service platform and ComplyTrust® SaaS Suite (CTSS), gain industry recognition for the architectural and business differentiators of the company product’s FMY data privacy, ComplyScan® (CS) compliance validation tool and our legacy C-DPS authentication/tamper-proof functionality, and generate sales and support revenues in FY21+.

 

CRITICAL ACCOUNTING POLICIES (AND ESTIMATES)

 

In preparing its consolidated financials statement, the Company follows GAAP, which is described in Note 3, Summary of Significant Accounting Policies, to the Company’s December 31, 2022 Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K. The application of these principles requires significant judgements or an estimation process that can affect the results of operations, financial position and cash flows of the Company, as well as the related footnote disclosures. The Company continually reviews its accounting policies and financials information disclosures. Except as noted in Note 3, Summary of Significant Accounting Policies, of the Company’s financials statements, there have been no material changes in the Company’s critical accounting policies or estimates since December 31, 2022.

 

 

RESULTS OF OPERATIONS

 

Sales

 

Sales for the nine-month period ended September 30, 2023 and 2022 were $Nil.

 

Cost of Sales

 

The cost of sales for the nine-month period ended September 30, 2023 and 2022 were $Nil.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses, consisting of product marketing liabilities, consulting fees, office, professional fees and other expenses to execute our business plan and for our day-to-day operations, decreased in the period ended September 30, 2023. We continue to develop and market C-DPS – Cloud Document Protection System and the “Right-to-be-Forgotten” and “Right-to-Erase” platform. Administrative expenses have decreased moderately as a result of insignificant fluctuations in general costs.

 

We have arranged for additional staff and consultants to engage in marketing activities in an effort to identify and assess appropriate market segments, develop business arrangements with prospective partners, create awareness of new products and services, and communicate to the industry and potential customers. Other components of selling, general and administrative expenses did not change significantly.

 

Nine-month period ended September 30, 2023

 

Selling, general and administrative expenses for the nine months ended September 30, 2023 decreased to $200,969 from $310,987 for the period ended September 30, 2022. We incurred decreased costs during the period due to minimal corporate and filing activities during the fiscal period.

 

Three-month period ended September 30, 2023

 

Selling, general and administrative expenses for the three months ended September 30, 2023 decreased to $79,049 from $116,163 for the period ended September 30, 2022. We incurred decreased costs during the period due to minimal corporate and filing activities during the fiscal period.

 

Research and Development

 

Nine-month period ended September 30, 2023

 

Research and development for the nine months ended September 30, 2023 decreased to $93,561 from $912,892 for the comparable period. This was a result of the Company’s effort to reduce costs due to the minimal activity during the period. We incurred comparable costs in 2022 as the management maintain its decision in 2021, to develop CTSS (ComplyScan®) as well as the on-going development of our subsidiary’s Forget-Me-Yes® zero trust data privacy platform. (“Right-to-be-Forgotten” and “Right-to-Erase”).

 

Three-month period ended September 30, 2023

 

Research and development for the three months ended September 30, 2023 decreased to $4,624 from $283,269 for the comparable period. This was a result of the Company’s effort to reduce costs due to the minimal activity during the period. We incurred comparable costs in 2022 as the management maintain its decision in 2021, to develop CTSS (ComplyScan®) as well as the on-going development of our subsidiary’s Forget-Me-Yes® zero trust data privacy platform. (“Right-to-be-Forgotten” and “Right-to-Erase”).

 

Net Losses

 

Nine-month period ended September 30, 2023

 

To date, we have not achieved profitability and expect to incur substantial losses for the foreseeable future. Our net loss for the nine months ended September 30, 2023 was $495,818, compared with a net loss of $1,649,986 for the comparative period.

 

Three-month period ended September 30, 2023

 

To date, we have not achieved profitability and expect to incur substantial losses for the foreseeable future. Our net loss for the three months ended September 30, 2023 was $140,507, compared with a net loss of $524,699 for the comparative period.

 

 

Liquidity and Capital Resources

 

At September 30, 2023 our cash and cash equivalents position was $239,682, a decrease from $687,602 at December 31, 2022. We had a working capital deficiency of $6,207 and an accumulated deficit of $48,291,252 at September 30, 2023.

 

We have historically satisfied our capital needs primarily by shareholders’ loans and issuing equity securities to our officers, directors, employees and a small group of investors, and from short-term bridge loans from members of management.

 

As of September 30, 2023, we had $239,682 in cash and cash equivalents. Management has forecasted the Company will not have sufficient working capital to operate for the ensuing 12 months. We will require an additional $3 million to $5 million to finance operations for the fiscal 2023 and we intend to obtain such financing through sales of our equity securities. While the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will be able to obtain adequate financing, or that such financing will be on terms acceptable to the Company, to meet future operational needs which may result in the delay, reduction, or discontinuation of ongoing development programs.

 

Assuming the aforementioned $3 million to $5 million in financing is obtained, continuing operations for the longer-term will be supported through anticipated growth in revenues and through additional sales of our securities. Although longer-term financing requirements may vary depending upon our sales performance, management expects that we will require additional financing of $3 million to $5 million for fiscal 2023. We have no binding commitments or arrangements for additional financing, and there is no assurance that management will be able to obtain any additional financing on terms acceptable to us, if at all.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

As of September 30, 2023, we have no off-balance sheet arrangements.

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

 

Oculus is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and is not required to provide information required under this Item.

 

Item 4.

Controls and Procedures.

 

We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, who is our principal executive officer, and Chief Financial Officer, who is our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

 

As of September 30, 2023, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting for the quarterly period ended September 30, 2023, identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15, that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II - OTHER INFORMATION

 

Item 1.

Legal Proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

 

Item 1A.

Risk Factors.

 

Oculus is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide information required under this Item. A description of the risks associated with our business, financial condition, and results of operations is set forth in Part I, Item 1A, of our Annual Report on Form 10 -K for the fiscal year ended December 31, 2022 filed with the SEC on March 28, 2023. Those factors continue to be meaningful for your evaluation of Oculus and we urge you to review and consider the risk factors presented in such Form 10-K.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3.

Defaults Upon Senior Securities.

 

None.

 

Item 4.

Mine Safety Disclosures.

 

Not applicable.

 

Item 5.

Other Information.

 

None.

 

Item 6.

Exhibits.

 

The information required by this Item is set forth on the exhibit index which follows the signature page of this report.

 

Exhibit

No.

Description

   

EX-31.1

Certification of CEO

   

EX-31.2

Certification of CFO

   

EX-32.1

SOX Certifiaction of CEO

   

EX-32.2

SOC Certification of CFO

 

101.INS

Inline XBRL Instance Document

   

101.SCH

Inline XBRL Taxonomy Extension Schema Document

   

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

   

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

   

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

   

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

   
104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

OCULUS VISIONTECH INC.

     

November 9th, 2023

By:

/s/ Rowland Perkins

 
   

Rowland Perkins

   

President and Chief Executive Officer

   

(principal executive officer)

     
     

November 9th, 2023

By:

/s/ Anton J. Drescher

 
   

Anton J. Drescher

   

Chief Financial Officer

   

(principal financial and accounting officer)

 

25
EX-31.1 2 ex_589577.htm EXHIBIT 31.1 ex_589577.htm

EXHIBIT 31.1

 

CERTIFICATION

 

I, Rowland Perkins, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Oculus VisionTech Inc..;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9th, 2023

By:

/s/ Rowland Perkins

 
   

Rowland Perkins

 
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 
EX-31.2 3 ex_589578.htm EXHIBIT 31.2 ex_589578.htm

EXHIBIT 31.2

 

CERTIFICATIONS

 

I, Anton J. Drescher, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Oculus VisionTech Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 9th, 2023

By:

/s/ Anton J. Drescher

   

Anton J. Drescher

   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 
EX-32.1 4 ex_589579.htm EXHIBIT 32.1 ex_589579.htm

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Oculus VisionTech Inc. (the “Company”), for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Rowland Perkins, Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date: November 9th, 2023

By:

/s/ Rowland Perkins

 
   

Rowland Perkins

 
   

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 
EX-32.2 5 ex_589580.htm EXHIBIT 32.2 ex_589580.htm

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Oculus VisionTech Inc. (the “Company”), for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anton J. Drescher , Chief Financial Officer for the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date: November 9th, 2023

By:

/s/ Anton J. Drescher

 
   

Anton J. Drescher

 
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

 

 

 
EX-101.SCH 6 ovtz-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation and Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Going Concern link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Common Stock link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Stock Options link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Warrants link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Selling, General and Administrative link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Research and Development link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Related Parties link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Financial Instruments and Risks link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Operating Leases link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Segmented Information link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Stock Options (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Selling, General and Administrative (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 10 - Research and Development (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 11 - Related Parties (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 2 - Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 6 - Common Stock (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stock Options (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 7 - Stock Options - Changes in Options (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 7 - Stock Options - Details of Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 8 - Warrants - Schedule of Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 10 - Research and Development - Research and Development (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 11 - Related Parties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 11 - Related Parties - Related Party Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 12 - Financial Instruments and Risks (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 13 - Operating Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 ovtz-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ovtz-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ovtz-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 3 - Summary of Significant Accounting Policies Note 4 - Prepaid Expenses and Other Current Assets Note 5 - Accounts Payable and Accrued Expenses Note 7 - Stock Options Note 8 - Warrants Note 9 - Selling, General and Administrative Note 10 - Research and Development Note 11 - Related Parties Accumulated other comprehensive loss Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Foreign Currency Transactions and Translations Policy [Policy Text Block] Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) Note 7 - Stock Options - Changes in Options (Details) Add back non-cash share-based compensation us-gaap_LiabilitiesCurrent Liabilities, Current Total current liabilities Note 7 - Stock Options - Details of Options Outstanding (Details) Note 8 - Warrants - Schedule of Warrants (Details) Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) Note 10 - Research and Development - Research and Development (Details) Note 11 - Related Parties - Related Party Expenses (Details) Earnings Per Share, Policy [Policy Text Block] Notes To Financial Statements Notes To Financial Statements [Abstract] Income Tax, Policy [Policy Text Block] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Currency translation differences Currency translation differences Research and Development Expense, Policy [Policy Text Block] Other comprehensive loss us-gaap_SharesIssued Balance (in shares) Balance (in shares) Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] Granted, aggregate intrinsic value (in dollars per share) Expired, aggregate intrinsic value (in dollars per share) Exercisable (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Remaining contractual life (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Options outstanding, aggregate intrinsic value Tax Receivable – Canadian GST Interest income Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average exercise price (in dollars per share) Common stock, shares authorized (in shares) Common Stock, Shares Authorized (in shares) Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Common stock, shares issued (in shares) Expired, weighted average exercise price (in dollars per share) Common stock, no par value (in dollars per share) Common Stock, No Par Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Granted, weighted average exercise price (in dollars per share) Lessee, Operating Leases [Text Block] us-gaap_AccountsPayableCurrent Accounts payable Ownership [Domain] Number of options outstanding (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options outstanding (in shares) Options outstanding (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired, options (in shares) Ownership [Axis] Preferred stock, issued (in shares) Preferred Stock, Shares Issued (in shares) Cash paid during the period for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Cash paid during the period for income taxes Prepaid expenses Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Preferred stock, no par value (in dollars per share) Goodwill and Intangible Assets, Policy [Policy Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized (in shares) Accrued fees and liabilities Expiry date us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Financial Instruments Disclosure [Text Block] Current Liabilities: Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] us-gaap_Assets Total Assets Supplemental disclosures of cash flow information: Plan Name [Axis] Plan Name [Domain] Consulting (Note 11) The aggregate costs incurred for consultation. Other Assets Disclosure [Text Block] Rent Operating Lease, Expense ovtz_WorkingCapitalDeficit Working Capital (Deficit) Represents the amount of difference between Current Assets and Current Liabilities. Statement [Line Items] Commitment to Issue Shares [Member] Represents commitment to issue shares. Additional paid in capital Share-Based Payment Arrangement [Text Block] AOCI Attributable to Parent [Member] Stockholders' Equity (Deficiency): Segment Reporting Disclosure [Text Block] Net loss us-gaap_NetIncomeLoss Net Income (Loss) Attributable to Parent Net loss us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period ASSETS Effect of foreign currency translation us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and cash equivalents Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Share-Based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Warrant [Member] us-gaap_PrepaidExpenseAndOtherAssetsCurrent Prepaid expenses and other current assets (Note 4) Prepaid Expense and Other Assets, Current Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Range Six [Member] Represents the range six. Expired (in dollars per share) Per share or per unit weighted average exercise price of warrants or rights expired during the period. Nonrelated Party [Member] us-gaap_CostsAndExpenses Loss from operations Expenses: Retained Earnings [Member] Consulting Fees [Member] Represents consulting fees paid. Increase (decrease) in accounts payable and accrued liabilities Related party transactions Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Common Stock [Member] Related Party Transactions Disclosure [Text Block] Schedule of Related Party Transactions [Table Text Block] Equity Components [Axis] Equity Component [Domain] Exercise price (in dollars per share) us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Number of warrants outstanding (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Warrants outstanding (in shares) Warrants outstanding (in shares) ovtz_ClassOfWarrantOrRightExpiredDuringPeriod Expired (in shares) The number of warrants or rights expired during period. Office and administration Vancouver, CA Operating Lease [Member] Represents the operating lease for the Vancouver, Candada location. ovtz_OperatingLeasesMonthlyRentExpense Operating Leases, Monthly Rent Expense Amount of monthly rent expense incurred under the operating lease. Increase (decrease) in accounts payable and accrued liabilities – related parties Vesting Every Six Months [Member] Represents the options vested every 6 months. Cash and cash equivalents us-gaap_CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value Stock-based compensation (Notes 7 and 11) Share-Based Payment Arrangement, Expense Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_ComprehensiveIncomeNetOfTax Total comprehensive loss Document Transition Report City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Related Party [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding, Ending Balance (in shares) Current Fiscal Year End Date Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Decrease in prepaid expenses and other current assets Selling, General and Administrative Disclosure [Text Block] The entire disclosure for selling, general and administrative expenses. Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Schedule of Selling, General and Administrative Expenses [Table Text Block] Tabular disclosure of selling, general and administrative expenses. Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] Entity File Number Entity Emerging Growth Company Document Type Filing and regulatory fees Expenditures for filing and regulatory. Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Share-based compensation Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Statement [Table] Ownership interest Entity Address, Address Line One Statement of Financial Position [Abstract] Weighted average number of common shares outstanding – basic and diluted (in shares) Accounts Payable and Accrued Liabilities Disclosure [Text Block] Entity Address, City or Town Entity Address, Postal Zip Code Net loss per share - basic and diluted (in dollars per share) Entity Address, State or Province Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] Income Statement [Abstract] Professional fees Marketing Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_TableTextBlock Notes Tables Related Party, Type [Axis] Related Party, Type [Domain] ComplyTrust Inc. [Member] Represents ComplyTrust Inc. ovtz_CommonStockSharesHeldInEscrow Common Stock, Shares Held in Escrow (in shares) Number of common stock held in escrow. Selling, general and administrative (Notes 9 and 11) Selling, General and Administrative Expense Granted, options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) Range Five [Member] Represents range five. Class of Warrant or Right [Text Block] The entire disclosure for warrant or right. Schedule of Warrants or Right [Table Text Block] Tabular disclosure of an entity's warrants or rights. Range Two [Member] Represents range two. Range Three [Member] Represents range three. Range Four [Member] Represents range four. Number of warrants exercisable (in shares) ovtz_ClassOfWarrantOrRightExercisable Number of warrants or rights exercisable. us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Stockholders' Equity (Deficiency) Remaining contractual life (Year) ovtz_ClassOfWarrantOrRightRemainingContractualTerm Remaining contractual term of class of warrant or right. Warrants Expiring on June 4, 2025 [Member] Represents warrants expiring on June 4, 2025. Related Party Transaction [Axis] Related Party Transaction [Domain] ovtz_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice Warrants outstanding, weighted average exercise price (in dollars per share) Warrants outstanding, weighted average exercise price (in dollars per share) Weighted average price of class of warrant or right outstanding. Payroll Research and development expense during the period related to payroll. Accumulated deficit Retained Earnings (Accumulated Deficit) Share-based Compensation [Member] Represents share-based compensation. Research and development (Note 10) Research and Development Expense Schedule of Research and Development Expenses [Table Text Block] Tabular disclosure of research and development expenses. Project management Research and development expense during the period related to project management. Research, Development, and Computer Software Disclosure [Text Block] Software development Business development Research and development expense during the period related to business development. Changes in operating assets and liabilities: us-gaap_StockholdersEquity Stockholders' equity (deficiency) Balance Balance ovtz_SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved Share-based Compensation Arrangement, Percent of Issued and Outstanding Common Shares Reserved The percent of issued and outstanding common shares reserved in a share-based compensation. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Substantial Doubt about Going Concern [Text Block] Class of Stock [Axis] Rolling Stock Option Plan [Member] Related to the Rolling Stock Option Plan. Exercise Price Range [Axis] Exercise Price Range [Domain] EX-101.PRE 10 ovtz-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 pic1.jpg begin 644 pic1.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2023
Nov. 09, 2023
Document Information [Line Items]    
Entity Central Index Key 0001107280  
Entity Registrant Name OCULUS VISIONTECH INC.  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 0-29651  
Entity Incorporation, State or Country Code WY  
Entity Tax Identification Number 06-1576391  
Entity Address, Address Line One Suite 507 - 837 West Hastings Street  
Entity Address, City or Town Vancouver  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V6C 3N6  
City Area Code 604  
Local Phone Number 685-1017  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   91,422,569
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
ASSETS    
Cash and cash equivalents $ 239,682 $ 687,602
Prepaid expenses and other current assets (Note 4) 7,447 30,238
Total Assets 247,129 717,840
Current Liabilities:    
Total current liabilities 253,336 302,423
Stockholders' Equity (Deficiency):    
Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 46,850,710 46,850,710
Additional paid in capital 1,470,933 1,394,997
Accumulated other comprehensive loss (36,598) (34,856)
Accumulated deficit (48,291,252) (47,795,434)
Stockholders' equity (deficiency) (6,207) 415,417
Total Liabilities and Stockholders' Equity (Deficiency) 247,129 717,840
Nonrelated Party [Member]    
Current Liabilities:    
Accounts payable and accrued expenses 103,226 133,796
Related Party [Member]    
Current Liabilities:    
Accounts payable and accrued expenses $ 150,110 $ 168,627
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
$ / shares in Thousands
Sep. 30, 2023
Dec. 31, 2022
Preferred stock, no par value (in dollars per share) $ 0 $ 0
Preferred stock, authorized (in shares) 250,000,000 250,000,000
Preferred stock, issued (in shares) 0 0
Common stock, no par value (in dollars per share) $ 0 $ 0
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 91,422,569 91,422,569
Common stock, shares outstanding (in shares) 91,422,569 91,422,569
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Expenses:        
Consulting (Note 11) $ 45,000 $ 45,000 $ 135,000 $ 90,000
Research and development (Note 10) 4,624 283,269 93,561 912,892
Selling, general and administrative (Notes 9 and 11) 79,049 116,163 200,696 310,987
Stock-based compensation (Notes 7 and 11) 14,923 80,267 75,936 336,107
Loss from operations (143,596) (524,699) (505,193) (1,649,986)
Interest income 3,089 0 9,375 0
Net loss (140,507) (524,699) (495,818) (1,649,986)
Other comprehensive loss        
Currency translation differences (1,878) (22,525) (1,742) (46,409)
Total comprehensive loss $ (142,385) $ (547,224) $ (497,560) $ (1,696,395)
Net loss per share - basic and diluted (in dollars per share) $ (0) $ (0.01) $ (0.01) $ (0.02)
Weighted average number of common shares outstanding – basic and diluted (in shares) 91,422,569 91,422,569 91,422,569 91,422,569
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Commitment to Issue Shares [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2021 91,422,569          
Balance at Dec. 31, 2021 $ 46,850,710 $ 998,477 $ 414,128 $ 6,190 $ (46,145,845) $ 2,123,660
Share-based compensation 0 336,107 0 0 0 336,107
Currency translation differences 0 0 0 (46,409) 0 (46,409)
Net loss $ 0 0 0 0 (1,649,986) (1,649,986)
Balance (in shares) at Sep. 30, 2022 91,422,569          
Balance at Sep. 30, 2022 $ 46,850,710 1,334,584 414,128 (40,219) (47,795,831) 763,372
Balance (in shares) at Dec. 31, 2021 91,422,569          
Balance at Dec. 31, 2021 $ 46,850,710 998,477 414,128 6,190 (46,145,845) 2,123,660
Net loss           (1,649,589)
Balance (in shares) at Dec. 31, 2022 91,422,569          
Balance at Dec. 31, 2022 $ 46,850,710 1,394,997   (34,856) (47,795,434) 415,417
Balance (in shares) at Jun. 30, 2022 91,422,569          
Balance at Jun. 30, 2022 $ 46,850,710 1,254,317 414,128 (17,694) (47,271,132) 1,230,329
Share-based compensation 0 80,267 0 0 0 80,267
Currency translation differences 0 0 0 (22,525) 0 (22,525)
Net loss $ 0 0 0 0 (524,699) (524,699)
Balance (in shares) at Sep. 30, 2022 91,422,569          
Balance at Sep. 30, 2022 $ 46,850,710 1,334,584 $ 414,128 (40,219) (47,795,831) 763,372
Balance (in shares) at Dec. 31, 2022 91,422,569          
Balance at Dec. 31, 2022 $ 46,850,710 1,394,997   (34,856) (47,795,434) 415,417
Share-based compensation 0 75,936   0 0 75,936
Currency translation differences 0 0   (1,742) 0 (1,742)
Net loss $ 0 0   0 (495,818) (495,818)
Balance (in shares) at Sep. 30, 2023 91,422,569          
Balance at Sep. 30, 2023 $ 46,850,710 1,470,933   (36,598) (48,291,252) (6,207)
Balance (in shares) at Jun. 30, 2023 91,422,569          
Balance at Jun. 30, 2023 $ 46,850,710 1,456,010   (34,720) (48,150,745) 121,255
Share-based compensation 0 14,923   0 0 14,923
Currency translation differences 0 0   (1,878) 0 (1,878)
Net loss $ 0 0   0 (140,507) (140,507)
Balance (in shares) at Sep. 30, 2023 91,422,569          
Balance at Sep. 30, 2023 $ 46,850,710 $ 1,470,933   $ (36,598) $ (48,291,252) $ (6,207)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Net loss $ (140,507) $ (524,699) $ (495,818) $ (1,649,986) $ (1,649,589)
Add back non-cash share-based compensation     75,936 336,107  
Changes in operating assets and liabilities:          
Decrease in prepaid expenses and other current assets     22,791 14,678  
Increase (decrease) in accounts payable and accrued liabilities     (30,570) 53,125  
Increase (decrease) in accounts payable and accrued liabilities – related parties     (18,517) 104,945  
Net cash used in operating activities     (446,178) (1,141,131)  
Effect of foreign currency translation     (1,742) (47,363)  
Net decrease in cash and cash equivalents     (447,920) (1,188,494)  
Cash and cash equivalents at beginning of period     687,602 2,208,451 2,208,451
Cash and cash equivalents at end of period $ 239,682 $ 1,019,957 239,682 1,019,957 $ 687,602
Supplemental disclosures of cash flow information:          
Cash paid during the period for interest     0 0  
Cash paid during the period for income taxes     $ 0 $ 0  
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Note 1 - Basis of Presentation and Business
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.

BASIS OF PRESENTATION AND BUSINESS

 

Oculus VisionTech, Inc. (the "Company") is a development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Substantially all of the Company's assets and substantially all its operations are located and conducted in the United States and Canada.

 

The unaudited condensed consolidated financial statements and notes herein should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed interim consolidated financial statements included herein have been prepared by the Company without audit, pursuant to the roles and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the SEC’s rules and regulations. Although management believes that the disclosures are adequate and make the information presented not misleading. In the opinion of management, all adjustments, which are of a normal and recurring nature (except as otherwise noted), that are necessary to present fairly the Company’s financial position as of September 30, 2023 and December 31, 2022, and its results of operation for the nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Note 2 - Going Concern
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Substantial Doubt about Going Concern [Text Block]

2.

GOING CONCERN

 

These condensed interim consolidated financial statements are prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses from inception and does not currently have the financial resources to sustain operations in the long-term. As shown in the financial statements, the Company has incurred a loss of $495,818 for the nine months ended September 30, 2023 and, in addition the Company incurred losses of $1,649,589 for the year ended December 31, 2022. As of September 30, 2023, the Company had an accumulated deficit of $48,291,252 and working capital deficiency of $6,207. As a result of the Company’s current financial position and challenging access to capital, there can be no assurance that the Company will be able raise additional funds in the future, in which case the Company will be unable to meet its financial obligations. These material uncertainties raise substantial doubt upon the Company’s ability to continue as a going concern. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. The Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations as they come due which management believes it will be able to do. To date, the Company has funded operations primarily through the issuance of common stock and warrants to outside investors and the Company’s management. The Company believes that its operations will generate additional funds and that additional funding from outside investors and the Company’s management will continue to be available to the Company when needed.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Note 3 - Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

3.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of consolidation

 

These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On November 14, 2023, the Board approved the condensed interim consolidated financial statements dated September 30, 2023.

 

These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.

 

Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.

 

The controlled entities are listed in the following table:

 

Name of Subsidiary

Country of

Incorporation

 

Ownership

Interest at

September 30,

2023

  

Ownership

Interest at

December 31,

2022

 

Principal Activity

           

ComplyTrust Inc.

US/Delaware

  100

%

  100

%

Software Development

 

Significant judgments, estimates and assumptions

 

The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.

 

The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following:

 

Significant judgments

 

the determination of functional currencies

 

share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.

 

Cash and cash equivalents

 

Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

 

Impairment of long-lived assets and long-lived assets to be disposed of

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.

 

Research and development

 

Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at September 30, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.

 

Intangible assets

 

Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.

 

The useful lives of intangible assets are assessed as either finite or indefinite.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.

 

Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.

 

Income taxes

 

The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

 

Net loss per share

 

Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended September 30, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 1,815,000 (2022: 5,415,000) stock options and 12,500,000 (2022: 17,400,000) warrants were excluded from the calculation.

 

Stock-based compensation

 

The Company follows the provisions of the Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.

 

The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.

 

Functional currency

 

The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.

 

In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.

 

Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.

 

Recently issued accounting pronouncements

 

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Note 4 - Prepaid Expenses and Other Current Assets
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Other Assets Disclosure [Text Block]

4.

PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consist of the following:

 

   

September 30,

   

December 31,

 
   

2023

   

2022

 
                 

Prepaid expenses

  $ 3,035     $ 28,028  

Tax Receivable – Canadian GST

    4,412       2,210  
    $ 7,447     $ 30,238  
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Note 5 - Accounts Payable and Accrued Expenses
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5.

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 

Accounts payable and accrued liabilities consist of the following:

 

   

September 30,

2023

   

December 31,

2022

 
                 

Accounts payable

  $ 85,532     $ 81,927  

Accrued fees and liabilities

    17,694       51,869  
    $ 103,226     $ 133,796  

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Note 6 - Common Stock
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Equity [Text Block]

6.

COMMON STOCK 

 

The Company has no par value common stock with 500,000,000 authorized shares and 91,422,569 outstanding on September 30, 2023 and December 31, 2022.

 

The Company has authorized the issuance of 250,000,000 non-voting preferred shares without par value, none issued.

 

As of September 30, 2023, there were Nil common shares held in escrow.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Note 7 - Stock Options
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

7.

STOCK OPTIONS

 

During the period ended September 30, 2023 and year ended December 31, 2022, the Company had a Rolling Stock Option Plan. Up to 10% of the Company’s issued and outstanding common shares may be reserved for granting of stock options. All of the options granted vest 20% every six months.

 

However, all options will be considered vested if one of the following criteria are met by the Company:

 

 i.Meeting sales forecasts:
  -The greater of either the 20% vesting every six months or based on a pro rata percentage of revenue earned by the Company’s subsidiary.
    
 ii.the listing of the Company on any national securities exchange.
    
 iii.a Change of Control Event.

 

During the period ended September 30, 2023, the Company did not grant any stock options and recorded $75,936 (2022: $336,107) of share-based compensation for vested portion that were previously granted.

 

The changes in options are as follows:

 

  

Number of

options

  

Weighted

average

exercise price

  

Aggregate

Intrinsic Value

 

Options outstanding, December 31, 2021

  5,315,000  $0.49  $- 

Granted

  100,000   0.80   - 

Options outstanding, December 31, 2022

  5,415,000  $0.50  $- 

Expired

  (3,600,000)  0.35   - 

Options outstanding, September 30, 2023

  1,815,000  $0.80  $- 

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at September 30, 2023.

 

Details of options outstanding as at September 30, 2023 are as follows:

 

Exercise price

(CAD)

  

Number of

options

outstanding

 

Expiry date

 

Number of options

exercisable

  

Remaining

contractual life (years)

 
                
$0.450   250,000 

December 21, 2023

  250,000   0.22 
$1.200   500,000 

January 29, 2024

  500,000   0.33 
$0.800   375,000 

June 10, 2024

  300,000   0.70 
$0.600   590,000 

October 14, 2024

  354,000   1.04 
$0.800   100,000 

January 31, 2025

  40,000   1.34 
                
     1,815,000    1,444,000     

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Note 8 - Warrants
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Class of Warrant or Right [Text Block]

8.

WARRANTS

 

The changes in warrants are as follows:

 

   

Number of

warrants

   

Weighted

average

exercise price

 

Warrants outstanding, December 31, 2021 and 2022

    17,400,000     $ 0.28  

Expired

    (4,900,000 )   $ 1.00  

Warrants outstanding, September 30, 2023

    12,500,000     $ 0.001  

 

Details of warrants outstanding as at September 30, 2023 are as follows:

 

Exercise price

       

Number of

warrants

outstanding

 

Expiry date

 

Number of

warrants

exercisable

   

Remaining

contractual life

(years)

 
                                   
$ 0.001 (1)  

(USA)

    12,500,000  

June 4, 2025

    -       1.68  
                                   
              12,500,000         -          

 

 

(1)

No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per ComplyTrust Inc.’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Note 9 - Selling, General and Administrative
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Selling, General and Administrative Disclosure [Text Block]

9.

SELLING, GENERAL AND ADMINISTRATIVE

 

The breakdown of selling, general and administrative for the period ended September 30, 2023 and 2022 is as follows:

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Filing and regulatory fees

  $ 8,514     $ 5,789     $ 26,557     $ 34,280  

Marketing

    -       19,359       -       73,053  

Professional fees

    13,614       20,733       39,722       67,882  

Rent

    10,936       10,249       32,587       28,807  

Office and administration

    45,985       60,033       101,830       106,963  
                                 
    $ 79,049     $ 116,163     $ 200,696     $ 310,987  
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Note 10 - Research and Development
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Research, Development, and Computer Software Disclosure [Text Block]

10.

RESEARCH AND DEVELOPMENT

 

The breakdown of research and development for the period ended September 30, 2023 and 2022 is as follows:

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Project management

  $ -     $ -     $ -     $ 11,990  

Software development

    4,624       203,687       59,123       677,035  

Business development

    -       33,435       3,952       99,636  

Payroll

    -       46,147       30,486       124,231  
                                 
    $ 4,624     $ 283,269     $ 93,561     $ 912,892  
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Note 11 - Related Parties
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

11.

RELATED PARTIES

 

Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.

 

The Company defines its key management as the Board of Directors, Chief Executive Officer, President, and Chief Financial Officer. Remuneration of directors and key management personnel of the Company for the period ended September 30, 2023 and 2022 was as follows:

 

       
  

2023

  

2022

 
         

Consulting

 $135,000  $90,000 

Selling general and administrative

  79,913   65,742 

Share-based compensation to directors and officers

  1,442   40,761 
  $216,355  $196,503 

 

The Company for the period ended September 30, 2023 and 2022 reimbursed a related party $79,913 and $65,742, respectively, for selling, general and administrative expenses paid on behalf of the Company. The Company incurred $135,000 (2022 - $90,000) of consulting fees accrued to a company controlled by a director of the Company for the period ended September 30, 2023 and 2022.

 

The Company also recorded share-based compensation of $1,442 (2022 - $40,761) for options vested to related parties during the period ended September 30, 2023 and 2022.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Note 12 - Financial Instruments and Risks
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Financial Instruments Disclosure [Text Block]

12.

FINANCIAL INSTRUMENTS AND RISKS

 

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are described below.

 

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

 

Fair value of financial instruments

 

The Company has various financial instruments including cash and cash equivalents, accounts payable and accrued liabilities, and accounts payable and accrued liabilities – related parties. The carrying values of accounts payable and accrued liabilities and accounts payable and accrued liabilities – related parties approximate their fair values due to the short-term nature of these financial instruments.

 

Cash and cash equivalents is carried at a level 1 fair value measurement.

 

The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:

 

Credit risk

The Company is exposed to credit risk only with respect to uncertainties as to timing and amount of collectability of receivables. The Company believes its credit risk is low because receivables is comprised of goods and services tax (GST) which is recoverable from the governing body in Canada. Management does not believe the receivables are impaired. The Company doesn’t believe there is significant credit risk associated with cash as these amounts are held with major Canadian banks.

 

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at September 30, 2023, the Company had a cash and cash equivalents balance of $239,682 ( December 31, 2022 – $687,602) to settle current liabilities of $253,336 ( December 31, 2022 – $302,423). All of the Company’s financial liabilities have contractual maturities of 30 days or due on demand and are subject to normal trade terms.

 

Interest rate risk

Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize such a loss is limited as it does not have any significant interest-bearing financial instruments.

 

Foreign currency risk

As at September 30, 2023 and December 31, 2022, the Company is exposed to foreign currency risk as certain monetary financial instruments are denominated in Canadian currency. The Company’s sensitivity analysis suggests that reasonably expected changes in the rates of exchange in the United States would change foreign exchange gain or loss by an insignificant amount.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Note 13 - Operating Leases
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

13.

OPERATING LEASES

 

The Company has one operating lease with unrelated third parties for office space at Vancouver, Canada.

 

The lease at the Vancouver, Canada location is on a month-to-month basis with monthly rental payments of $3,950 (CND). For the period ended September 30, 2023 and 2022 rent expense was $31,066 and $27,288, respectively.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Note 14 - Segmented Information
9 Months Ended
Sep. 30, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

14.

SEGMENTED INFORMATION

 

The Company currently operates in a single reportable operating segment. All of the Company’s assets and expenditures are located in Canada and the United States.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Basis of consolidation

 

These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On November 14, 2023, the Board approved the condensed interim consolidated financial statements dated September 30, 2023.

 

These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.

 

Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than 50% of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.

 

The controlled entities are listed in the following table:

 

Name of Subsidiary

Country of

Incorporation

 

Ownership

Interest at

September 30,

2023

  

Ownership

Interest at

December 31,

2022

 

Principal Activity

           

ComplyTrust Inc.

US/Delaware

  100

%

  100

%

Software Development

 

Use of Estimates, Policy [Policy Text Block]

Significant judgments, estimates and assumptions

 

The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.

 

The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are not limited to the following:

 

Significant judgments

 

the determination of functional currencies

 

share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.

 

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents

 

Cash equivalents include highly liquid investments with original maturities of twelve months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

 

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of long-lived assets and long-lived assets to be disposed of

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.

 

Research and Development Expense, Policy [Policy Text Block]

Research and development

 

Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at September 30, 2023 , it was not yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.

 

Goodwill and Intangible Assets, Policy [Policy Text Block]

Intangible assets

 

Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.

 

The useful lives of intangible assets are assessed as either finite or indefinite.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset may be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.

 

Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets may be impaired.

 

Income Tax, Policy [Policy Text Block]

Income taxes

 

The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

 

Earnings Per Share, Policy [Policy Text Block]

Net loss per share

 

Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that may require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended September 30, 2023, this calculation proved to be anti-dilutive, and therefore the Company’s 1,815,000 (2022: 5,415,000) stock options and 12,500,000 (2022: 17,400,000) warrants were excluded from the calculation.

 

Share-Based Payment Arrangement [Policy Text Block]

Stock-based compensation

 

The Company follows the provisions of the Accounting Standards Codification Section 718 “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.

 

The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.

 

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Functional currency

 

The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.

 

In accordance with ASC 830, Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.

 

Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are not re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recently issued accounting pronouncements

 

The Company has reviewed new and revised accounting pronouncements that have been issued but are not yet effective. The Company does not expect any material impact from future accounting pronouncements.

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Note 3 - Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]

Name of Subsidiary

Country of

Incorporation

 

Ownership

Interest at

September 30,

2023

  

Ownership

Interest at

December 31,

2022

 

Principal Activity

           

ComplyTrust Inc.

US/Delaware

  100

%

  100

%

Software Development

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Note 4 - Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
   

September 30,

   

December 31,

 
   

2023

   

2022

 
                 

Prepaid expenses

  $ 3,035     $ 28,028  

Tax Receivable – Canadian GST

    4,412       2,210  
    $ 7,447     $ 30,238  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Note 5 - Accounts Payable and Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
   

September 30,

2023

   

December 31,

2022

 
                 

Accounts payable

  $ 85,532     $ 81,927  

Accrued fees and liabilities

    17,694       51,869  
    $ 103,226     $ 133,796  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Note 7 - Stock Options (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of

options

  

Weighted

average

exercise price

  

Aggregate

Intrinsic Value

 

Options outstanding, December 31, 2021

  5,315,000  $0.49  $- 

Granted

  100,000   0.80   - 

Options outstanding, December 31, 2022

  5,415,000  $0.50  $- 

Expired

  (3,600,000)  0.35   - 

Options outstanding, September 30, 2023

  1,815,000  $0.80  $- 
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise price

(CAD)

  

Number of

options

outstanding

 

Expiry date

 

Number of options

exercisable

  

Remaining

contractual life (years)

 
                
$0.450   250,000 

December 21, 2023

  250,000   0.22 
$1.200   500,000 

January 29, 2024

  500,000   0.33 
$0.800   375,000 

June 10, 2024

  300,000   0.70 
$0.600   590,000 

October 14, 2024

  354,000   1.04 
$0.800   100,000 

January 31, 2025

  40,000   1.34 
                
     1,815,000    1,444,000     
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Note 8 - Warrants (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Schedule of Warrants or Right [Table Text Block]
   

Number of

warrants

   

Weighted

average

exercise price

 

Warrants outstanding, December 31, 2021 and 2022

    17,400,000     $ 0.28  

Expired

    (4,900,000 )   $ 1.00  

Warrants outstanding, September 30, 2023

    12,500,000     $ 0.001  

Exercise price

       

Number of

warrants

outstanding

 

Expiry date

 

Number of

warrants

exercisable

   

Remaining

contractual life

(years)

 
                                   
$ 0.001 (1)  

(USA)

    12,500,000  

June 4, 2025

    -       1.68  
                                   
              12,500,000         -          
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Note 9 - Selling, General and Administrative (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Schedule of Selling, General and Administrative Expenses [Table Text Block]
   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Filing and regulatory fees

  $ 8,514     $ 5,789     $ 26,557     $ 34,280  

Marketing

    -       19,359       -       73,053  

Professional fees

    13,614       20,733       39,722       67,882  

Rent

    10,936       10,249       32,587       28,807  

Office and administration

    45,985       60,033       101,830       106,963  
                                 
    $ 79,049     $ 116,163     $ 200,696     $ 310,987  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Note 10 - Research and Development (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Schedule of Research and Development Expenses [Table Text Block]
   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2023

   

2022

   

2023

   

2022

 
                                 

Project management

  $ -     $ -     $ -     $ 11,990  

Software development

    4,624       203,687       59,123       677,035  

Business development

    -       33,435       3,952       99,636  

Payroll

    -       46,147       30,486       124,231  
                                 
    $ 4,624     $ 283,269     $ 93,561     $ 912,892  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Note 11 - Related Parties (Tables)
9 Months Ended
Sep. 30, 2023
Notes Tables  
Schedule of Related Party Transactions [Table Text Block]
       
  

2023

  

2022

 
         

Consulting

 $135,000  $90,000 

Selling general and administrative

  79,913   65,742 

Share-based compensation to directors and officers

  1,442   40,761 
  $216,355  $196,503 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Note 2 - Going Concern (Details Textual) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Net Income (Loss) Attributable to Parent $ (140,507) $ (524,699) $ (495,818) $ (1,649,986) $ (1,649,589)
Retained Earnings (Accumulated Deficit) (48,291,252)   (48,291,252)   $ (47,795,434)
Working Capital (Deficit) $ 6,207   $ 6,207    
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Note 3 - Summary of Significant Accounting Policies (Details Textual) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1,815,000 5,415,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 12,500,000 17,400,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)
Sep. 30, 2023
Dec. 31, 2022
ComplyTrust Inc. [Member]    
Ownership interest 100.00% 100.00%
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Prepaid expenses $ 3,035 $ 28,028
Tax Receivable – Canadian GST 4,412 2,210
Prepaid Expense and Other Assets, Current $ 7,447 $ 30,238
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - Nonrelated Party [Member] - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Accounts payable $ 85,532 $ 81,927
Accrued fees and liabilities 17,694 51,869
Accounts Payable and Accrued Liabilities, Current $ 103,226 $ 133,796
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Note 6 - Common Stock (Details Textual) - $ / shares
$ / shares in Thousands
Sep. 30, 2023
Dec. 31, 2022
Common Stock, No Par Value (in dollars per share) $ 0 $ 0
Common Stock, Shares Authorized (in shares) 500,000,000 500,000,000
Common Stock, Shares, Outstanding, Ending Balance (in shares) 91,422,569 91,422,569
Preferred Stock, Shares Authorized (in shares) 250,000,000 250,000,000
Preferred Stock, Shares Issued (in shares) 0 0
Common Stock, Shares Held in Escrow (in shares) 0  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Note 7 - Stock Options (Details Textual) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         100,000
Share-Based Payment Arrangement, Expense $ 14,923 $ 80,267 $ 75,936 $ 336,107  
Rolling Stock Option Plan [Member]          
Share-based Compensation Arrangement, Percent of Issued and Outstanding Common Shares Reserved 10.00%   10.00%    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)     0    
Share-Based Payment Arrangement, Expense     $ 75,936 $ 336,107  
Rolling Stock Option Plan [Member] | Vesting Every Six Months [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage     20.00%    
Rolling Stock Option Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage     20.00%    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Note 7 - Stock Options - Changes in Options (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Options outstanding (in shares) 5,415,000 5,315,000  
Options outstanding, weighted average exercise price (in dollars per share) $ 0.5 $ 0.49  
Options outstanding, aggregate intrinsic value $ 0 $ 0 $ 0
Granted, options (in shares)   100,000  
Granted, weighted average exercise price (in dollars per share)   $ 0.8  
Granted, aggregate intrinsic value (in dollars per share)   $ 0  
Expired, options (in shares) (3,600,000)    
Expired, weighted average exercise price (in dollars per share) $ 0.35    
Expired, aggregate intrinsic value (in dollars per share) $ 0    
Options outstanding (in shares) 1,815,000 5,415,000  
Options outstanding, weighted average exercise price (in dollars per share) $ 0.8 $ 0.5  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Note 7 - Stock Options - Details of Options Outstanding (Details) - shares
9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Number of options outstanding (in shares) 1,815,000 5,415,000 5,315,000
Exercisable (in shares) 1,444,000    
Range Two [Member]      
Number of options outstanding (in shares) 250,000    
Expiry date Dec. 21, 2023    
Exercisable (in shares) 250,000    
Remaining contractual life (Year) 2 months 19 days    
Range Three [Member]      
Number of options outstanding (in shares) 500,000    
Expiry date Jan. 29, 2024    
Exercisable (in shares) 500,000    
Remaining contractual life (Year) 3 months 29 days    
Range Four [Member]      
Number of options outstanding (in shares) 375,000    
Expiry date Jun. 10, 2024    
Exercisable (in shares) 300,000    
Remaining contractual life (Year) 8 months 12 days    
Range Five [Member]      
Number of options outstanding (in shares) 590,000    
Expiry date Oct. 14, 2024    
Exercisable (in shares) 354,000    
Remaining contractual life (Year) 1 year 14 days    
Range Six [Member]      
Number of options outstanding (in shares) 100,000    
Expiry date Jan. 31, 2025    
Exercisable (in shares) 40,000    
Remaining contractual life (Year) 1 year 4 months 2 days    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Note 8 - Warrants - Schedule of Warrants (Details)
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Warrants outstanding (in shares) 17,400,000
Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares $ 0.28
Expired (in shares) (4,900,000)
Expired (in dollars per share) | $ / shares $ 1
Warrants outstanding (in shares) 12,500,000
Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares $ 0.001
Number of warrants outstanding (in shares) 12,500,000
Number of warrants exercisable (in shares) 0
Warrants Expiring on June 4, 2025 [Member]  
Warrants outstanding (in shares) 12,500,000
Exercise price (in dollars per share) | $ / shares $ 0.001 [1]
Number of warrants outstanding (in shares) 12,500,000
Number of warrants exercisable (in shares) 0
Remaining contractual life (Year) 1 year 8 months 4 days
[1] No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per ComplyTrust Inc.’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Filing and regulatory fees $ 8,514 $ 5,789 $ 26,557 $ 34,280
Marketing 0 19,359 0 73,053
Professional fees 13,614 20,733 39,722 67,882
Rent 10,936 10,249 32,587 28,807
Office and administration 45,985 60,033 101,830 106,963
Selling, General and Administrative Expense $ 79,049 $ 116,163 $ 200,696 $ 310,987
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Note 10 - Research and Development - Research and Development (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Project management $ 0 $ 0 $ 0 $ 11,990
Software development 4,624 203,687 59,123 677,035
Business development 0 33,435 3,952 99,636
Payroll 0 46,147 30,486 124,231
Research and Development Expense $ 4,624 $ 283,269 $ 93,561 $ 912,892
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Note 11 - Related Parties (Details Textual) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Related Party Transaction, Amounts of Transaction $ 216,355 $ 196,503
Consulting Fees [Member]    
Related Party Transaction, Amounts of Transaction 135,000 90,000
Selling, General and Administrative Expenses [Member]    
Related Party Transaction, Amounts of Transaction 79,913 65,742
Share-based Compensation [Member]    
Related Party Transaction, Amounts of Transaction $ 1,442 $ 40,761
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Note 11 - Related Parties - Related Party Expenses (Details) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Related party transactions $ 216,355 $ 196,503
Consulting Fees [Member]    
Related party transactions 135,000 90,000
Selling, General and Administrative Expenses [Member]    
Related party transactions 79,913 65,742
Share-based Compensation [Member]    
Related party transactions $ 1,442 $ 40,761
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Note 12 - Financial Instruments and Risks (Details Textual) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Cash and Cash Equivalents, at Carrying Value $ 239,682 $ 687,602
Liabilities, Current $ 253,336 $ 302,423
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Note 13 - Operating Leases (Details Textual)
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
CAD ($)
Sep. 30, 2022
USD ($)
Operating Lease, Expense $ 10,936 $ 10,249 $ 32,587   $ 28,807
Vancouver, CA Operating Lease [Member]          
Operating Leases, Monthly Rent Expense       $ 3,950  
Operating Lease, Expense     $ 31,066   $ 27,288
XML 57 ovtz20230930_10q_htm.xml IDEA: XBRL DOCUMENT 0001107280 2023-01-01 2023-09-30 0001107280 2023-11-09 0001107280 2023-09-30 0001107280 2022-12-31 0001107280 us-gaap:NonrelatedPartyMember 2023-09-30 0001107280 us-gaap:NonrelatedPartyMember 2022-12-31 0001107280 us-gaap:RelatedPartyMember 2023-09-30 0001107280 us-gaap:RelatedPartyMember 2022-12-31 0001107280 2023-07-01 2023-09-30 0001107280 2022-07-01 2022-09-30 0001107280 2022-01-01 2022-09-30 0001107280 us-gaap:CommonStockMember 2022-12-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001107280 us-gaap:RetainedEarningsMember 2022-12-31 0001107280 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001107280 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001107280 us-gaap:CommonStockMember 2023-09-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001107280 us-gaap:RetainedEarningsMember 2023-09-30 0001107280 us-gaap:CommonStockMember 2023-06-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001107280 us-gaap:RetainedEarningsMember 2023-06-30 0001107280 2023-06-30 0001107280 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001107280 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001107280 us-gaap:CommonStockMember 2021-12-31 0001107280 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001107280 ovtz:CommitmentToIssueSharesMember 2021-12-31 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001107280 us-gaap:RetainedEarningsMember 2021-12-31 0001107280 2021-12-31 0001107280 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001107280 ovtz:CommitmentToIssueSharesMember 2022-01-01 2022-09-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001107280 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001107280 us-gaap:CommonStockMember 2022-09-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001107280 ovtz:CommitmentToIssueSharesMember 2022-09-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001107280 us-gaap:RetainedEarningsMember 2022-09-30 0001107280 2022-09-30 0001107280 us-gaap:CommonStockMember 2022-06-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001107280 ovtz:CommitmentToIssueSharesMember 2022-06-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001107280 us-gaap:RetainedEarningsMember 2022-06-30 0001107280 2022-06-30 0001107280 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001107280 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001107280 ovtz:CommitmentToIssueSharesMember 2022-07-01 2022-09-30 0001107280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001107280 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001107280 2022-01-01 2022-12-31 0001107280 ovtz:ComplytrustIncMember 2023-09-30 0001107280 ovtz:ComplytrustIncMember 2022-12-31 0001107280 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001107280 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001107280 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001107280 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001107280 ovtz:RollingStockOptionPlanMember 2023-09-30 0001107280 ovtz:RollingStockOptionPlanMember ovtz:VestingEverySixMonthsMember 2023-01-01 2023-09-30 0001107280 ovtz:RollingStockOptionPlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-09-30 0001107280 ovtz:RollingStockOptionPlanMember 2023-01-01 2023-09-30 0001107280 ovtz:RollingStockOptionPlanMember 2022-01-01 2022-09-30 0001107280 ovtz:RangeTwoMember 2023-09-30 0001107280 ovtz:RangeTwoMember 2023-01-01 2023-09-30 0001107280 ovtz:RangeThreeMember 2023-09-30 0001107280 ovtz:RangeThreeMember 2023-01-01 2023-09-30 0001107280 ovtz:RangeFourMember 2023-09-30 0001107280 ovtz:RangeFourMember 2023-01-01 2023-09-30 0001107280 ovtz:RangeFiveMember 2023-09-30 0001107280 ovtz:RangeFiveMember 2023-01-01 2023-09-30 0001107280 ovtz:RangeSixMember 2023-09-30 0001107280 ovtz:RangeSixMember 2023-01-01 2023-09-30 0001107280 ovtz:WarrantsExpiringOnJune42025Member 2023-09-30 0001107280 ovtz:WarrantsExpiringOnJune42025Member 2023-01-01 2023-09-30 0001107280 ovtz:ConsultingFeesMember 2023-01-01 2023-09-30 0001107280 ovtz:ConsultingFeesMember 2022-01-01 2022-09-30 0001107280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001107280 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001107280 ovtz:SharebasedCompensationMember 2023-01-01 2023-09-30 0001107280 ovtz:SharebasedCompensationMember 2022-01-01 2022-09-30 0001107280 ovtz:ConsultingFeesMember 2023-01-01 2023-09-30 0001107280 ovtz:ConsultingFeesMember 2022-01-01 2022-09-30 0001107280 ovtz:VancouverCAOperatingLeaseMember 2023-01-01 2023-09-30 0001107280 ovtz:VancouverCAOperatingLeaseMember 2022-01-01 2022-09-30 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y iso4217:CAD 0001107280 OCULUS VISIONTECH INC. false --12-31 Q3 2023 0 0 250000000 250000000 0 0 0 0 500000000 500000000 91422569 91422569 91422569 91422569 -0 0 500000000 91422569 0 0 2023-12-21 2024-01-29 2024-06-10 2024-10-14 2025-01-31 0.001 10-Q true 2023-09-30 false 0-29651 WY 06-1576391 Suite 507 - 837 West Hastings Street Vancouver BC V6C 3N6 604 685-1017 Yes Yes Non-accelerated Filer true false false 91422569 239682 687602 7447 30238 247129 717840 103226 133796 150110 168627 253336 302423 46850710 46850710 1470933 1394997 -36598 -34856 -48291252 -47795434 -6207 415417 247129 717840 45000 45000 135000 90000 4624 283269 93561 912892 79049 116163 200696 310987 14923 80267 75936 336107 143596 524699 505193 1649986 3089 0 9375 0 -140507 -524699 -495818 -1649986 -1878 -22525 -1742 -46409 -142385 -547224 -497560 -1696395 -0.01 -0.01 -0.02 91422569 91422569 91422569 91422569 91422569 46850710 1394997 -34856 -47795434 415417 0 75936 0 0 75936 0 0 -1742 0 -1742 0 0 0 -495818 -495818 91422569 46850710 1470933 -36598 -48291252 -6207 91422569 46850710 1456010 -34720 -48150745 121255 0 14923 0 0 14923 0 0 -1878 0 -1878 0 0 0 -140507 -140507 91422569 46850710 1470933 -36598 -48291252 -6207 91422569 46850710 998477 414128 6190 -46145845 2123660 0 336107 0 0 0 336107 0 0 0 -46409 0 -46409 0 0 0 0 -1649986 -1649986 91422569 46850710 1334584 414128 -40219 -47795831 763372 91422569 46850710 1254317 414128 -17694 -47271132 1230329 0 80267 0 0 0 80267 0 0 0 -22525 0 -22525 0 0 0 0 -524699 -524699 91422569 46850710 1334584 414128 -40219 -47795831 763372 -495818 -1649986 75936 336107 -22791 -14678 -30570 53125 -18517 104945 -446178 -1141131 -1742 -47363 -447920 -1188494 687602 2208451 239682 1019957 0 0 0 0 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a href="#" id="notes" title="notes"></a><em style="font: inherit;">1.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>BASIS OF PRESENTATION AND BUSINESS</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Oculus VisionTech, Inc. (the "<i>Company</i>") is a development-stage technology company focused on cyber security, data privacy and data protection solutions for Enterprise business customers. Substantially all of the Company's assets and substantially all its operations are located and conducted in the United States and Canada.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The unaudited condensed consolidated financial statements and notes herein should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto, included in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2022. </em>The condensed interim consolidated financial statements included herein have been prepared by the Company without audit, pursuant to the roles and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the SEC’s rules and regulations. Although management believes that the disclosures are adequate and make the information presented <em style="font: inherit;">not</em> misleading. In the opinion of management, all adjustments, which are of a normal and recurring nature (except as otherwise noted), that are necessary to present fairly the Company’s financial position as of <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;"> December 31, 2022, </em>and its results of operation for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022,</em> and cash flows for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>GOING CONCERN </b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These condensed interim consolidated financial statements are prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses from inception and does <em style="font: inherit;">not</em> currently have the financial resources to sustain operations in the long-term. As shown in the financial statements, the Company has incurred a loss of $495,818 for the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2023 </em>and, in addition the Company incurred losses of $1,649,589 for the year ended <em style="font: inherit;"> December 31, 2022. </em>As of <em style="font: inherit;"> September 30, 2023, </em>the Company had an accumulated deficit of $48,291,252 and working capital deficiency of $6,207. As a result of the Company’s current financial position and challenging access to capital, there can be <em style="font: inherit;">no</em> assurance that the Company will be able raise additional funds in the future, in which case the Company will be unable to meet its financial obligations. These material uncertainties raise substantial doubt upon the Company’s ability to continue as a going concern. The financial statements do <em style="font: inherit;">not</em> include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. The Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations as they come due which management believes it will be able to do. To date, the Company has funded operations primarily through the issuance of common stock and warrants to outside investors and the Company’s management. The Company believes that its operations will generate additional funds and that additional funding from outside investors and the Company’s management will continue to be available to the Company when needed.</p> -495818 -1649589 -48291252 6207 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em></b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Basis of consolidation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On <em style="font: inherit;"> November 14, 2023, </em>the Board approved the condensed interim consolidated financial statements dated <em style="font: inherit;"> September 30, 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than <em style="font: inherit;">50%</em> of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The controlled entities are listed in the following table:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 23.4%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Name of Subsidiary</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23.4%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Country of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporation</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Ownership</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interest at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Ownership</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interest at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23.2%; border-top: 1px solid black; padding-bottom: 1px; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Principal Activity</p> </td></tr> <tr style="vertical-align: bottom;"><td style="text-align: center;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ComplyTrust Inc.</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">US/Delaware</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Software Development</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Significant judgments, estimates and assumptions</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are <em style="font: inherit;">not</em> limited to the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Significant judgments</span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the determination of functional currencies</p> </td></tr> <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cash and cash equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cash equivalents include highly liquid investments with original maturities of <em style="font: inherit;">twelve</em> months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Impairment of long-lived assets and long-lived assets to be disposed of</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Research and development </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at <em style="font: inherit;"> September 30, 2023 , </em>it was <em style="font: inherit;">not</em> yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Intangible assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The useful lives of intangible assets are assessed as either finite or indefinite.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset <em style="font: inherit;"> may </em>be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets <em style="font: inherit;"> may </em>be impaired.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Income taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than <em style="font: inherit;">not</em> that some portion or the entire deferred tax asset will <em style="font: inherit;">not</em> be recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Net loss per share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that <em style="font: inherit;"> may </em>require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended <em style="font: inherit;"> September 30, 2023, </em>this calculation proved to be anti-dilutive, and therefore the Company’s 1,815,000 (<em style="font: inherit;">2022:</em> 5,415,000) stock options and 12,500,000 (<em style="font: inherit;">2022:</em> 17,400,000) warrants were excluded from the calculation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Stock-based compensation </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company follows the provisions of the Accounting Standards Codification Section <em style="font: inherit;">718</em> “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Functional currency</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In accordance with ASC <em style="font: inherit;">830,</em> Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are <em style="font: inherit;">not</em> re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b></b></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Recently issued accounting pronouncements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has reviewed new and revised accounting pronouncements that have been issued but are <em style="font: inherit;">not</em> yet effective. The Company does <em style="font: inherit;">not</em> expect any material impact from future accounting pronouncements.</p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Basis of consolidation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These condensed interim consolidated financial statements are presented in United States dollars and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). On <em style="font: inherit;"> November 14, 2023, </em>the Board approved the condensed interim consolidated financial statements dated <em style="font: inherit;"> September 30, 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These condensed interim consolidated financial statements include the financial statements of the Company and the entities controlled by the Company. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Control is defined as the exposure, or rights, to variable returns from involvement with an investee and the ability to affect those returns through power over the investee. Power over an investee exists when an investor has existing rights that give it the ability to direct the activities that significantly affect the investee’s returns. This control is generally evidenced through owning more than <em style="font: inherit;">50%</em> of the voting rights or currently exercisable potential voting rights of a Company’s capital stock. All significant intercompany transactions and balances have been eliminated.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The controlled entities are listed in the following table:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 23.4%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Name of Subsidiary</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23.4%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Country of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporation</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Ownership</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interest at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Ownership</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interest at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23.2%; border-top: 1px solid black; padding-bottom: 1px; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Principal Activity</p> </td></tr> <tr style="vertical-align: bottom;"><td style="text-align: center;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ComplyTrust Inc.</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">US/Delaware</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Software Development</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 23.4%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Name of Subsidiary</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23.4%; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Country of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Incorporation</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Ownership</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interest at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">September 30,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Ownership</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Interest at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2022</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid black;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 23.2%; border-top: 1px solid black; padding-bottom: 1px; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Principal Activity</p> </td></tr> <tr style="vertical-align: bottom;"><td style="text-align: center;"> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ComplyTrust Inc.</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">US/Delaware</em></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Software Development</em></p> </td></tr> </tbody></table> 1 1 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Significant judgments, estimates and assumptions</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the period. These judgments, estimates and assumptions are regularly evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While management believes the estimates to be reasonable, actual results could differ from those estimates and could impact future results of operations and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The areas which require significant judgment and estimates that management has made at the financial reporting date, that could result in a material change to the carrying amounts of assets and liabilities, in the event actual results differ from the assumptions made, relate to, but are <em style="font: inherit;">not</em> limited to the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Significant judgments</span></p> <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the determination of functional currencies</p> </td></tr> <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">●</p> </td><td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">share-based compensation and warrants issued in connection with private placements, using the fair value method. The Company uses the Black-Scholes option pricing model to determine the fair value of share-based compensation. This estimate also requires determining the most appropriate inputs to the valuation model. The main factor affecting the estimates of the fair value of stock options is the stock price, expected volatility used and the expected duration of the instrument. The Company currently estimates the expected volatility of its common shares based on historical stock price information.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Cash and cash equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cash equivalents include highly liquid investments with original maturities of <em style="font: inherit;">twelve</em> months or less, and which are subject to an insignificant risk of change in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Impairment of long-lived assets and long-lived assets to be disposed of</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount and the fair value less costs to sell.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Research and development </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Expenditures on research activities is recognized on the consolidated statement of operations and comprehensive loss as incurred. Development expenditures are capitalized as part of the cost of the resulting intangible asset only if the expenditures can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. Management determined that as at <em style="font: inherit;"> September 30, 2023 , </em>it was <em style="font: inherit;">not</em> yet able to demonstrate with sufficient certainty that it is probable that any economic benefits will flow to the Company. Accordingly, all research and development costs incurred to date have been expensed.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Intangible assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Identifiable intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is valued at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The useful lives of intangible assets are assessed as either finite or indefinite.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment annually and whenever there is an indication that the intangible asset <em style="font: inherit;"> may </em>be impaired. The amortization period and method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. The amortization expense on intangible assets with finite lives is recognized in profit or loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intangible assets with indefinite lives are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis and more frequently if there are indicators that intangible assets <em style="font: inherit;"> may </em>be impaired.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Income taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for income taxes under the asset and liability method. Current income taxes are the expected taxes payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to taxes payable in respect of previous years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the asset and liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than <em style="font: inherit;">not</em> that some portion or the entire deferred tax asset will <em style="font: inherit;">not</em> be recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Net loss per share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Basic loss per share is calculated using the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or contracts that <em style="font: inherit;"> may </em>require the issuance of common shares in the future were converted, unless the impact is anti-dilutive. For the period ended <em style="font: inherit;"> September 30, 2023, </em>this calculation proved to be anti-dilutive, and therefore the Company’s 1,815,000 (<em style="font: inherit;">2022:</em> 5,415,000) stock options and 12,500,000 (<em style="font: inherit;">2022:</em> 17,400,000) warrants were excluded from the calculation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> 1815000 5415000 12500000 17400000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Stock-based compensation </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company follows the provisions of the Accounting Standards Codification Section <em style="font: inherit;">718</em> “Compensation - Stock Compensation”, which establishes accounting for equity-based compensation awards to be accounted for using the fair value method. Equity-settled share-based payment arrangements are initially measured at fair value at the date of grant and recorded within shareholders’ equity. Arrangements considered to be cash-settled are initially recorded at fair value and classified as accrued liabilities, and subsequently re-measured at fair value at each reporting date. The Company’s stock option plan is an equity-settled arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value at grant date of all share-based payments is recognized as compensation expense over the period for which benefits of services are expected to be derived, with a corresponding credit to shareholders’ equity or accrued liabilities depending on whether they are equity-settled or cash-settled. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model and estimate the expected forfeiture rate at the date of grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Functional currency</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s consolidated financial statements are presented in U.S. dollars, which is the Company’s reporting currency. The functional currency of Oculus VisionTech Inc. is the Canadian (“CAD” or “C”) dollar and the functional currency of ComplyTrust Inc. is the U.S. dollar.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In accordance with ASC <em style="font: inherit;">830,</em> Foreign Currency Matters, for companies that have a functional currency other than the US dollar, the Company translates the assets and liabilities into U.S. dollars using the rate of exchange prevailing at the balance sheet date and the statements of operations and comprehensive loss and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation from CAD into U.S. dollars are recorded in shareholders' equity as part of accumulated other comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Foreign currency transactions are translated into the functional currency of the respective currency of the entity or division, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in foreign currency at period-end exchange rates are recognized in profit or loss. Non-monetary items that are <em style="font: inherit;">not</em> re-translated at period end are measured at historical cost (translated using the exchange rates at the transaction date), except for non-monetary items measured at fair value, which are translated using the exchange rates as at the date when fair value was determined. Gains and losses are recorded in the statement of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Recently issued accounting pronouncements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has reviewed new and revised accounting pronouncements that have been issued but are <em style="font: inherit;">not</em> yet effective. The Company does <em style="font: inherit;">not</em> expect any material impact from future accounting pronouncements.</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">December 31,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,035</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,028</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax Receivable – Canadian GST</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,412</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,210</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,447</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">December 31,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid expenses</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,035</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,028</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax Receivable – Canadian GST</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,412</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,210</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,447</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 3035 28028 4412 2210 7447 30238 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">5.</em></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Accounts payable and accrued liabilities consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85,532</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,927</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued fees and liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,694</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,869</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">103,226</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,796</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 3px double black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">December 31,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 3px double black; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts payable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85,532</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81,927</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued fees and liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,694</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">51,869</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">103,226</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">133,796</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 85532 81927 17694 51869 103226 133796 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>COMMON STOCK</b> </p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has no par value common stock with 500,000,000 authorized shares and 91,422,569 outstanding on <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has authorized the issuance of 250,000,000 non-voting preferred shares without par value, none issued.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> September 30, 2023, </em>there were <span style="-sec-ix-hidden:c104455934">Nil</span> common shares held in escrow.</p> 0 500000000 91422569 250000000 0 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>STOCK OPTIONS</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the period ended <em style="font: inherit;"> September 30, 2023 </em>and year ended <em style="font: inherit;"> December 31, 2022, </em>the Company had a Rolling Stock Option Plan. Up to 10% of the Company’s issued and outstanding common shares <em style="font: inherit;"> may </em>be reserved for granting of stock options. All of the options granted vest 20% every <em style="font: inherit;">six</em> months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">However, all options will be considered vested if <em style="font: inherit;">one</em> of the following criteria are met by the Company:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 6%;"> </td><td style="width: 2%;">i.</td><td colspan="2" rowspan="1" style="width: 14%;">Meeting sales forecasts:</td></tr> <tr><td style="width: 6%;"> </td><td style="width: 2%;"> </td><td style="width: 14%;">-</td><td style="width: 78%;">The greater of either the 20% vesting every <em style="font: inherit;">six</em> months or based on a pro rata percentage of revenue earned by the Company’s subsidiary.</td></tr> <tr><td style="width: 6%;"> </td><td style="width: 2%;"> </td><td style="width: 14%;"> </td><td style="width: 78%;"> </td></tr> <tr><td style="width: 6%;"> </td><td style="width: 2%;">ii.</td><td colspan="2" rowspan="1" style="width: 14%;">the listing of the Company on any national securities exchange.</td></tr> <tr><td style="width: 6%;"> </td><td style="width: 2%;"> </td><td style="width: 14%;"> </td><td style="width: 78%;"> </td></tr> <tr><td style="width: 6%;"> </td><td style="width: 2%;">iii.</td><td colspan="2" rowspan="1" style="width: 14%;">a Change of Control Event.</td></tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the period ended <em style="font: inherit;"> September 30, 2023, </em>the Company did <span style="-sec-ix-hidden:c104455946">not</span> grant any stock options and recorded $75,936 (<em style="font: inherit;">2022:</em> $336,107) of share-based compensation for vested portion that were previously granted.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The changes in options are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt; margin-right: auto;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt; text-indent: 6pt;"><b><b>Number of</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt; text-indent: 6pt;"><b><b>options</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>exercise price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>Aggregate </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>Intrinsic Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options outstanding, December 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>5,315,000</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>0.49</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>-</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options outstanding, December 31, 2022 </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>5,415,000</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>0.50</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>-</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,600,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options outstanding, September 30, 2023 </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>1,815,000</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>0.80</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>-</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options that were in-the-money at <em style="font: inherit;"> September 30, 2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Details of options outstanding as at <em style="font: inherit;"> September 30, 2023 </em>are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><b>Exercise price </b></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(CAD)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>Number of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>options</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b>Expiry date</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Number of options</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>exercisable</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>Remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>contractual life (years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 21%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455968">December 21, 2023</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455972">January 29, 2024</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">375,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455976">June 10, 2024</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">300,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">590,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455980">October 14, 2024</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">354,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455984">January 31, 2025</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 21%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,815,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,444,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> 0.10 0.20 0.20 75936 336107 <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 27pt; margin-right: auto;"><tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt; text-indent: 6pt;"><b><b>Number of</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt; text-indent: 6pt;"><b><b>options</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>Weighted</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>exercise price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>Aggregate </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><b><b>Intrinsic Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options outstanding, December 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>5,315,000</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>0.49</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>-</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options outstanding, December 31, 2022 </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>5,415,000</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>0.50</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>-</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,600,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Options outstanding, September 30, 2023 </b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>1,815,000</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>0.80</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>-</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table> 5315000 0.49 0 100000 0.8 0 5415000 0.5 0 3600000 0.35 0 1815000 0.8 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><b>Exercise price </b></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(CAD)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>Number of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>options</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>outstanding</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b>Expiry date</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Number of options</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>exercisable</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>Remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b>contractual life (years)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-top: 1px solid black; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 21%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455968">December 21, 2023</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455972">January 29, 2024</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">500,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">375,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455976">June 10, 2024</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">300,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.600</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">590,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455980">October 14, 2024</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">354,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><span style="-sec-ix-hidden:c104455984">January 31, 2025</span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 21%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 17%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,815,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 21%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 17%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,444,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 17%; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td></tr> </tbody></table> 250000 250000 P0Y2M19D 500000 500000 P0Y3M29D 375000 300000 P0Y8M12D 590000 354000 P1Y14D 100000 40000 P1Y4M2D 1815000 1444000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em> </b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>WARRANTS</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The changes in warrants are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:6pt;"><b><b>Number of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:6pt;"><b><b>warrants</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>average </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>exercise price</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Warrants outstanding, December 31, 2021 and 2022 </b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>17,400,000</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>0.28</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,900,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Warrants outstanding, September 30, 2023</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>12,500,000</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>0.001</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Details of warrants outstanding as at <em style="font: inherit;"> September 30, 2023 </em>are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><b><b>Exercise price</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>Number of </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>warrants</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>outstanding</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b>Expiry date</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>Number of </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>warrants</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>exercisable</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>Remaining </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>contractual life </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>(years)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 4%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 20%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.001</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"><sup style="vertical-align:top;line-height:120%;"><em style="font: inherit;">(1)</em></sup></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="-sec-ix-hidden:c104456005">(USA)</span></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><em style="font: inherit;">June 4, 2025</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.68</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 4%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 20%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 4%;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 20%;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(<em style="font: inherit;">1</em>)</p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><em style="font: inherit;">No</em> share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being <em style="font: inherit;">1</em>) revenue sales projections per ComplyTrust Inc.’s <em style="font: inherit;">5</em>-year proformas, or <em style="font: inherit;">2</em>) listing on a major US exchange, or <em style="font: inherit;">3</em>) change of control.</p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:6pt;"><b><b>Number of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:6pt;"><b><b>warrants</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>average </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><b>exercise price</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Warrants outstanding, December 31, 2021 and 2022 </b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>17,400,000</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>$</b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>0.28</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,900,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Warrants outstanding, September 30, 2023</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>12,500,000</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>0.001</b></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><b><b>Exercise price</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 4%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>Number of </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>warrants</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>outstanding</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b>Expiry date</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>Number of </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>warrants</b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>exercisable</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>Remaining </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>contractual life </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><b><b><b>(years)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 4%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 20%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.001</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"><sup style="vertical-align:top;line-height:120%;"><em style="font: inherit;">(1)</em></sup></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="-sec-ix-hidden:c104456005">(USA)</span></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><em style="font: inherit;">June 4, 2025</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.68</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 4%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 20%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 16%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 4%;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,500,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 20%;"><em style="font: inherit;"> </em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> </tbody> </table> 17400000 0.28 4900000 1 12500000 0.001 12500000 0 P1Y8M4D 12500000 0 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em> </b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>SELLING, GENERAL AND ADMINISTRATIVE</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The breakdown of selling, general and administrative for the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Three months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Nine months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Filing and regulatory fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,514</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,789</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">26,557</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">34,280</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketing</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,359</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">73,053</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">13,614</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">20,733</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">39,722</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">67,882</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Rent</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,936</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,249</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">32,587</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">28,807</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Office and administration</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">45,985</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">60,033</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">101,830</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">106,963</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">79,049</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">116,163</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">200,696</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">310,987</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Three months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Nine months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Filing and regulatory fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,514</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,789</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">26,557</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">34,280</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketing</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,359</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">73,053</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">13,614</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">20,733</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">39,722</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">67,882</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Rent</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,936</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,249</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">32,587</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">28,807</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Office and administration</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">45,985</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">60,033</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">101,830</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">106,963</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">79,049</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">116,163</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">200,696</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">310,987</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 8514 5789 26557 34280 0 19359 0 73053 13614 20733 39722 67882 10936 10249 32587 28807 45985 60033 101830 106963 79049 116163 200696 310987 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em> </b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>RESEARCH AND DEVELOPMENT</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The breakdown of research and development for the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Three months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Nine months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Project management</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">11,990</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Software development</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,624</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">203,687</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">59,123</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">677,035</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Business development</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">33,435</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,952</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">99,636</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">46,147</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">30,486</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">124,231</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">4,624</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">283,269</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">93,561</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">912,892</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Three months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="6" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Nine months ended</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Project management</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">11,990</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Software development</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,624</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">203,687</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">59,123</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">677,035</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Business development</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">33,435</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,952</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">99,636</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Payroll</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">46,147</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">30,486</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">124,231</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">4,624</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">283,269</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">93,561</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">912,892</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 0 0 0 11990 4624 203687 59123 677035 0 33435 3952 99636 0 46147 30486 124231 4624 283269 93561 912892 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>RELATED PARTIES</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Related parties include the Board of Directors, officers, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company defines its key management as the Board of Directors, Chief Executive Officer, President, and Chief Financial Officer. Remuneration of directors and key management personnel of the Company for the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Consulting</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">135,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">90,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling general and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79,913</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">65,742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation to directors and officers</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,761</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,355</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">196,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company for the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> reimbursed a related party $79,913 and $65,742, respectively, for selling, general and administrative expenses paid on behalf of the Company. The Company incurred $135,000 (<em style="font: inherit;">2022</em> - $90,000) of consulting fees accrued to a company controlled by a director of the Company for the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company also recorded share-based compensation of $1,442 (<em style="font: inherit;">2022</em> - $40,761) for options vested to related parties during the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022.</em></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2022</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Consulting</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">135,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">90,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling general and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79,913</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">65,742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation to directors and officers</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,761</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">216,355</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">196,503</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> </tbody></table> 135000 90000 79913 65742 1442 40761 216355 196503 79913 65742 135000 90000 1442 40761 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>FINANCIAL INSTRUMENTS AND RISKS</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Financial instruments measured at fair value are classified into <em style="font: inherit;">one</em> of <em style="font: inherit;">three</em> levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The <em style="font: inherit;">three</em> levels of the fair value hierarchy are described below.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Level <em style="font: inherit;">1</em> - quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Level <em style="font: inherit;">2</em> – inputs other than quoted prices included in Level <em style="font: inherit;">1</em> that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Level <em style="font: inherit;">3</em> - inputs for the asset or liability that are <em style="font: inherit;">not</em> based on observable market data (unobservable inputs).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Fair value of financial instruments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has various financial instruments including cash and cash equivalents, accounts payable and accrued liabilities, and accounts payable and accrued liabilities – related parties. The carrying values of accounts payable and accrued liabilities and accounts payable and accrued liabilities – related parties approximate their fair values due to the short-term nature of these financial instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cash and cash equivalents is carried at a level <em style="font: inherit;">1</em> fair value measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s risk exposures and the impact on the Company’s financial instruments are summarized below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Credit risk </i></b></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company is exposed to credit risk only with respect to uncertainties as to timing and amount of collectability of receivables. The Company believes its credit risk is low because receivables is comprised of goods and services tax (GST) which is recoverable from the governing body in Canada. Management does <em style="font: inherit;">not</em> believe the receivables are impaired. The Company doesn’t believe there is significant credit risk associated with cash as these amounts are held with major Canadian banks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Liquidity risk </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Liquidity risk is the risk that the Company will <em style="font: inherit;">not</em> be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at <em style="font: inherit;"> September 30, 2023, </em>the Company had a cash and cash equivalents balance of $239,682 (<em style="font: inherit;"> December 31, 2022 – </em>$687,602) to settle current liabilities of $253,336 (<em style="font: inherit;"> December 31, 2022 – </em>$302,423). All of the Company’s financial liabilities have contractual maturities of <em style="font: inherit;">30</em> days or due on demand and are subject to normal trade terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Interest rate risk </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Interest rate risk is the risk that the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize such a loss is limited as it does <em style="font: inherit;">not</em> have any significant interest-bearing financial instruments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Foreign currency risk </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As at <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;"> December 31, 2022, </em>the Company is exposed to foreign currency risk as certain monetary financial instruments are denominated in Canadian currency. The Company’s sensitivity analysis suggests that reasonably expected changes in the rates of exchange in the United States would change foreign exchange gain or loss by an insignificant amount.</p> 239682 687602 253336 302423 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em> </b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>OPERATING LEASES</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has <em style="font: inherit;">one</em> operating lease with unrelated <em style="font: inherit;">third</em> parties for office space at Vancouver, Canada.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The lease at the Vancouver, Canada location is on a month-to-month basis with monthly rental payments of $3,950 (CND). For the period ended <em style="font: inherit;"> September 30, 2023 </em>and <em style="font: inherit;">2022</em> rent expense was $31,066 and $27,288, respectively.</p> 3950 31066 27288 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 45pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">14.</em> </b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>SEGMENTED INFORMATION</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company currently operates in a single reportable operating segment. All of the Company’s assets and expenditures are located in Canada and the United States.</p> No share purchase warrants are exercisable until specific performance criteria have been met. Such criteria being 1) revenue sales projections per ComplyTrust Inc.’s 5-year proformas, or 2) listing on a major US exchange, or 3) change of control. EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 94 141 1 true 24 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) Sheet http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited Condensed Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited Condensed Interim Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation and Business Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business Note 1 - Basis of Presentation and Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Going Concern Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern Note 2 - Going Concern Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies- Note 3 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets Note 4 - Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses Note 5 - Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Common Stock Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock Note 6 - Common Stock Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Stock Options Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options Note 7 - Stock Options Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Warrants Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants Note 8 - Warrants Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Selling, General and Administrative Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative Note 9 - Selling, General and Administrative Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Research and Development Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development Note 10 - Research and Development Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Related Parties Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties Note 11 - Related Parties Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Financial Instruments and Risks Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks- Note 12 - Financial Instruments and Risks Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Operating Leases Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases Note 13 - Operating Leases Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Segmented Information Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information Note 14 - Segmented Information Notes 20 false false R21.htm 020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies- 21 false false R22.htm 021 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables Note 3 - Summary of Significant Accounting Policies (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies- 22 false false R23.htm 022 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables Note 4 - Prepaid Expenses and Other Current Assets (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets 23 false false R24.htm 023 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables Note 5 - Accounts Payable and Accrued Expenses (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses 24 false false R25.htm 024 - Disclosure - Note 7 - Stock Options (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables Note 7 - Stock Options (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options 25 false false R26.htm 025 - Disclosure - Note 8 - Warrants (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables Note 8 - Warrants (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants 26 false false R27.htm 026 - Disclosure - Note 9 - Selling, General and Administrative (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables Note 9 - Selling, General and Administrative (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative 27 false false R28.htm 027 - Disclosure - Note 10 - Research and Development (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables Note 10 - Research and Development (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development 28 false false R29.htm 028 - Disclosure - Note 11 - Related Parties (Tables) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables Note 11 - Related Parties (Tables) Tables http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties 29 false false R30.htm 029 - Disclosure - Note 2 - Going Concern (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual Note 2 - Going Concern (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern 30 false false R31.htm 030 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables 31 false false R32.htm 031 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details) Details 32 false false R33.htm 032 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) Details 33 false false R34.htm 033 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) Details 34 false false R35.htm 034 - Disclosure - Note 6 - Common Stock (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual Note 6 - Common Stock (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock 35 false false R36.htm 035 - Disclosure - Note 7 - Stock Options (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual Note 7 - Stock Options (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables 36 false false R37.htm 036 - Disclosure - Note 7 - Stock Options - Changes in Options (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details Note 7 - Stock Options - Changes in Options (Details) Details 37 false false R38.htm 037 - Disclosure - Note 7 - Stock Options - Details of Options Outstanding (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details Note 7 - Stock Options - Details of Options Outstanding (Details) Details 38 false false R39.htm 038 - Disclosure - Note 8 - Warrants - Schedule of Warrants (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details Note 8 - Warrants - Schedule of Warrants (Details) Details 39 false false R40.htm 039 - Disclosure - Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details) Details 40 false false R41.htm 040 - Disclosure - Note 10 - Research and Development - Research and Development (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details Note 10 - Research and Development - Research and Development (Details) Details 41 false false R42.htm 041 - Disclosure - Note 11 - Related Parties (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual Note 11 - Related Parties (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables 42 false false R43.htm 042 - Disclosure - Note 11 - Related Parties - Related Party Expenses (Details) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details Note 11 - Related Parties - Related Party Expenses (Details) Details 43 false false R44.htm 043 - Disclosure - Note 12 - Financial Instruments and Risks (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual Note 12 - Financial Instruments and Risks (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks- 44 false false R45.htm 044 - Disclosure - Note 13 - Operating Leases (Details Textual) Sheet http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual Note 13 - Operating Leases (Details Textual) Details http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases 45 false false All Reports Book All Reports ovtz-20230930.xsd ovtz-20230930_cal.xml ovtz-20230930_def.xml ovtz-20230930_lab.xml ovtz-20230930_pre.xml ovtz20230930_10q.htm pic1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ovtz20230930_10q.htm": { "nsprefix": "ovtz", "nsuri": "http://www.oculusvisiontech.com/20230930", "dts": { "schema": { "local": [ "ovtz-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ovtz-20230930_cal.xml" ] }, "definitionLink": { "local": [ "ovtz-20230930_def.xml" ] }, "labelLink": { "local": [ "ovtz-20230930_lab.xml" ] }, "presentationLink": { "local": [ "ovtz-20230930_pre.xml" ] }, "inline": { "local": [ "ovtz20230930_10q.htm" ] } }, "keyStandard": 122, "keyCustom": 19, "axisStandard": 11, "axisCustom": 0, "memberStandard": 10, "memberCustom": 13, "hidden": { "total": 32, "http://fasb.org/us-gaap/2023": 25, "http://www.oculusvisiontech.com/20230930": 1, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 94, "entityCount": 1, "segmentCount": 24, "elementCount": 227, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 373, "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Interim Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R3": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Interim Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "ovtz:ConsultingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "ovtz:ConsultingExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited", "longName": "004 - Statement - Condensed Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited)", "shortName": "Condensed Interim Consolidated Statements of Stockholders' Equity (Deficiency) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-01-01_2022-09-30_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R6": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "longName": "005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R7": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business", "longName": "006 - Disclosure - Note 1 - Basis of Presentation and Business", "shortName": "Note 1 - Basis of Presentation and Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern", "longName": "007 - Disclosure - Note 2 - Going Concern", "shortName": "Note 2 - Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "longName": "008 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "shortName": "Note 3 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets", "longName": "009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses", "longName": "010 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses", "shortName": "Note 5 - Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock", "longName": "011 - Disclosure - Note 6 - Common Stock", "shortName": "Note 6 - Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "longName": "012 - Disclosure - Note 7 - Stock Options", "shortName": "Note 7 - Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants", "longName": "013 - Disclosure - Note 8 - Warrants", "shortName": "Note 8 - Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ClassOfWarrantOrRightTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ClassOfWarrantOrRightTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative", "longName": "014 - Disclosure - Note 9 - Selling, General and Administrative", "shortName": "Note 9 - Selling, General and Administrative", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development", "longName": "015 - Disclosure - Note 10 - Research and Development", "shortName": "Note 10 - Research and Development", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "longName": "016 - Disclosure - Note 11 - Related Parties", "shortName": "Note 11 - Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-", "longName": "017 - Disclosure - Note 12 - Financial Instruments and Risks", "shortName": "Note 12 - Financial Instruments and Risks", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "longName": "018 - Disclosure - Note 13 - Operating Leases", "shortName": "Note 13 - Operating Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information", "longName": "019 - Disclosure - Note 14 - Segmented Information", "shortName": "Note 14 - Segmented Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies", "longName": "020 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "longName": "021 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "longName": "022 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "longName": "023 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Note 5 - Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables", "longName": "024 - Disclosure - Note 7 - Stock Options (Tables)", "shortName": "Note 7 - Stock Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables", "longName": "025 - Disclosure - Note 8 - Warrants (Tables)", "shortName": "Note 8 - Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables", "longName": "026 - Disclosure - Note 9 - Selling, General and Administrative (Tables)", "shortName": "Note 9 - Selling, General and Administrative (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables", "longName": "027 - Disclosure - Note 10 - Research and Development (Tables)", "shortName": "Note 10 - Research and Development (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables", "longName": "028 - Disclosure - Note 11 - Related Parties (Tables)", "shortName": "Note 11 - Related Parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual", "longName": "029 - Disclosure - Note 2 - Going Concern (Details Textual)", "shortName": "Note 2 - Going Concern (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "longName": "030 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "longName": "031 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)", "shortName": "Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2023-09-30_OwnershipAxis-ComplytrustIncMember", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30_OwnershipAxis-ComplytrustIncMember", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "longName": "032 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "longName": "033 - Disclosure - Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)", "shortName": "Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-NonrelatedPartyMember", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual", "longName": "034 - Disclosure - Note 6 - Common Stock (Details Textual)", "shortName": "Note 6 - Common Stock (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": null, "uniqueAnchor": null }, "R36": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual", "longName": "035 - Disclosure - Note 7 - Stock Options (Details Textual)", "shortName": "Note 7 - Stock Options (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "d_2022-01-01_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_PlanNameAxis-RollingStockOptionPlanMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R37": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "longName": "036 - Disclosure - Note 7 - Stock Options - Changes in Options (Details)", "shortName": "Note 7 - Stock Options - Changes in Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R38": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details", "longName": "037 - Disclosure - Note 7 - Stock Options - Details of Options Outstanding (Details)", "shortName": "Note 7 - Stock Options - Details of Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R39": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details", "longName": "038 - Disclosure - Note 8 - Warrants - Schedule of Warrants (Details)", "shortName": "Note 8 - Warrants - Schedule of Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "td", "tr", "tbody", "table", "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "td", "tr", "tbody", "table", "ovtz:ScheduleOfWarrantsOrRightTableTextBlock", "ovtz:ClassOfWarrantOrRightTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "longName": "039 - Disclosure - Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details)", "shortName": "Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "ovtz:FilingAndRegulatoryFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "ovtz:FilingAndRegulatoryFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details", "longName": "040 - Disclosure - Note 10 - Research and Development - Research and Development (Details)", "shortName": "Note 10 - Research and Development - Research and Development (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "ovtz:ResearchAndDevelopmentExpenseProjectManagement", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "ovtz:ResearchAndDevelopmentExpenseProjectManagement", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "longName": "041 - Disclosure - Note 11 - Related Parties (Details Textual)", "shortName": "Note 11 - Related Parties (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_RelatedPartyTransactionAxis-ConsultingFeesMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R43": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details", "longName": "042 - Disclosure - Note 11 - Related Parties - Related Party Expenses (Details)", "shortName": "Note 11 - Related Parties - Related Party Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2023-01-01_2023-09-30", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_IncomeStatementLocationAxis-ConsultingFeesMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } }, "R44": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual", "longName": "043 - Disclosure - Note 12 - Financial Instruments and Risks (Details Textual)", "shortName": "Note 12 - Financial Instruments and Risks (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual", "longName": "044 - Disclosure - Note 13 - Operating Leases (Details Textual)", "shortName": "Note 13 - Operating Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ovtz:ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "ovtz:SellingGeneralAndAdministrativeDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-09-30_LeaseContractualTermAxis-VancouverCAOperatingLeaseMember", "name": "ovtz:OperatingLeasesMonthlyRentExpense", "unitRef": "CAD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "ovtz20230930_10q.htm", "unique": true } } }, "tag": { "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Remaining contractual life (Year)", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r64" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "ovtz_statement-statement-note-7-stock-options-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-7-stock-options-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Stock Options" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r45", "r286" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r45", "r155" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r25", "r26", "r27", "r70", "r71", "r72", "r73" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r23", "r24" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Stockholders' Equity (Deficiency)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r51", "r67", "r261", "r341", "r363", "r369", "r401" ] }, "ovtz_statement-statement-note-8-warrants-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-8-warrants-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Warrants" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding \u2013 basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r112", "r117" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r342", "r343", "r346", "r347", "r348", "r349" ] }, "ovtz_statement-statement-note-9-selling-general-and-administrative-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-9-selling-general-and-administrative-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Selling, General and Administrative" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative (Notes 9 and 11)", "totalLabel": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r55" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "terseLabel": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r77", "r335" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash paid during the period for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r19", "r22" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r21" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r59", "r94" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss per share - basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r89", "r104", "r105", "r106", "r107", "r108", "r112", "r113", "r115", "r116", "r117", "r119", "r220", "r221", "r257", "r264", "r338" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r66", "r78", "r96", "r125", "r128", "r131", "r138", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r208", "r210", "r222", "r258", "r298", "r341", "r351", "r370", "r371", "r405" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets" ], "lang": { "en-us": { "role": { "label": "Other Assets Disclosure [Text Block]", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "us-gaap_NetIncomeLoss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r53", "r58", "r68", "r75", "r80", "r82", "r87", "r96", "r102", "r104", "r105", "r106", "r107", "r110", "r111", "r114", "r125", "r127", "r130", "r133", "r138", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r221", "r222", "r262", "r306", "r324", "r325", "r339", "r350", "r370" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Expiry date", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth_ref": [ "r374" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary." } } }, "auth_ref": [ "r7", "r38" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r366", "r367", "r400", "r408", "r412" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "lang": { "en-us": { "role": { "label": "Rent", "terseLabel": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r403" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Decrease in prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation (Notes 7 and 11)", "terseLabel": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r185", "r196" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r46", "r286" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "terseLabel": "Common Stock, Shares, Outstanding, Ending Balance (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r46", "r286", "r304", "r412", "r413" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r47", "r341", "r409" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r84", "r200", "r201", "r202", "r203", "r204", "r205", "r273" ] }, "ovtz_WarrantsExpiringOnJune42025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "WarrantsExpiringOnJune42025Member", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring on June 4, 2025 [Member]", "documentation": "Represents warrants expiring on June 4, 2025." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r30" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r352" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "lang": { "en-us": { "role": { "label": "Office and administration", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r55", "r308" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Accrued fees and liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r143", "r144", "r311" ] }, "ovtz_statement-statement-note-3-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r23" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r144", "r311" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r81", "r83", "r88", "r256", "r263" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r12" ] }, "ovtz_statement-statement-note-10-research-and-development-research-and-development-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-10-research-and-development-research-and-development-details", "lang": { "en-us": { "role": { "label": "Note 10 - Research and Development - Research and Development (Details)" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "Granted, aggregate intrinsic value (in dollars per share)", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r179" ] }, "ovtz_statement-statement-note-10-research-and-development-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-10-research-and-development-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Research and Development" } } }, "auth_ref": [] }, "ovtz_statement-statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "lang": { "en-us": { "role": { "label": "Note 9 - Selling, General and Administrative - Selling, General and Administrative Expenses (Details)" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details" ], "lang": { "en-us": { "role": { "label": "Software development", "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed." } } }, "auth_ref": [ "r42", "r399" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "ovtz_VestingEverySixMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "VestingEverySixMonthsMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting Every Six Months [Member]", "documentation": "Represents the options vested every 6 months." } } }, "auth_ref": [] }, "ovtz_statement-statement-note-11-related-parties-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-11-related-parties-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Related Parties" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableCurrent", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r11", "r341" ] }, "us-gaap_MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketingExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "lang": { "en-us": { "role": { "label": "Marketing", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } }, "auth_ref": [ "r55" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price (in dollars per share)", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r167" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r34" ] }, "ovtz_statement-statement-note-7-stock-options-details-of-options-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-7-stock-options-details-of-options-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 7 - Stock Options - Details of Options Outstanding (Details)" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "totalLabel": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Tax Receivable \u2013 Canadian GST", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r40", "r357" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "ovtz_statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r170", "r173", "r180", "r181", "r182", "r183", "r184", "r192", "r193", "r194", "r195" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r353" ] }, "ovtz_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "ovtz_statement-statement-note-7-stock-options-changes-in-options-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-7-stock-options-changes-in-options-details", "lang": { "en-us": { "role": { "label": "Note 7 - Stock Options - Changes in Options (Details)" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r354" ] }, "ovtz_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Expired, options (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r178" ] }, "ovtz_statement-statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "lang": { "en-us": { "role": { "label": "Note 5 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r99", "r100", "r101", "r120", "r243", "r272", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r307", "r308", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r326", "r345" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r233" ] }, "ovtz_statement-statement-note-8-warrants-schedule-of-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-8-warrants-schedule-of-warrants-details", "lang": { "en-us": { "role": { "label": "Note 8 - Warrants - Schedule of Warrants (Details)" } } }, "auth_ref": [] }, "ovtz_statement-statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies - Summary of Subsidiary (Details)" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "Options outstanding, aggregate intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r30" ] }, "ovtz_statement-statement-note-11-related-parties-related-party-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-11-related-parties-related-party-expenses-details", "lang": { "en-us": { "role": { "label": "Note 11 - Related Parties - Related Party Expenses (Details)" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of warrants outstanding (in shares)", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodStartLabel": "Warrants outstanding (in shares)", "periodEndLabel": "Warrants outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of options outstanding (in shares)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Options outstanding (in shares)", "periodEndLabel": "Options outstanding (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r174", "r175" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "Expired, aggregate intrinsic value (in dollars per share)", "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Options outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r174", "r175" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercisable (in shares)", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development" ], "lang": { "en-us": { "role": { "label": "Research, Development, and Computer Software Disclosure [Text Block]", "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period." } } }, "auth_ref": [ "r69", "r199" ] }, "ovtz_statement-statement-note-5-accounts-payable-and-accrued-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "statement-statement-note-5-accounts-payable-and-accrued-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Accounts Payable and Accrued Expenses" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r355" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ovtz_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "WorkingCapitalDeficit", "crdr": "debit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual" ], "lang": { "en-us": { "role": { "label": "ovtz_WorkingCapitalDeficit", "terseLabel": "Working Capital (Deficit)", "documentation": "Represents the amount of difference between Current Assets and Current Liabilities." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Deficiency):" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r121", "r122", "r123", "r124", "r125", "r126", "r129", "r131", "r132", "r133", "r134", "r135", "r136", "r137" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r5", "r28" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Stockholders' equity (deficiency)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r46", "r49", "r50", "r60", "r288", "r304", "r327", "r328", "r341", "r351", "r363", "r369", "r401", "r412" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r197" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r62", "r95", "r154", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r168", "r218", "r329", "r331", "r334" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r359" ] }, "us-gaap_CommonStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNoParValue", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value (in dollars per share)", "terseLabel": "Common Stock, No Par Value (in dollars per share)", "documentation": "Face amount per share of no-par value common stock." } } }, "auth_ref": [ "r46" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern" ], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Granted, options (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r177" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "ovtz_SharebasedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "SharebasedCompensationMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation [Member]", "documentation": "Represents share-based compensation." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "ovtz_VancouverCAOperatingLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "VancouverCAOperatingLeaseMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Vancouver, CA Operating Lease [Member]", "documentation": "Represents the operating lease for the Vancouver, Candada location." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r29" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r46", "r259", "r341" ] }, "ovtz_SellingGeneralAndAdministrativeDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "SellingGeneralAndAdministrativeDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Disclosure [Text Block]", "documentation": "The entire disclosure for selling, general and administrative expenses." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Add back non-cash share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r352" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "terseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r35", "r36", "r171" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-" ], "lang": { "en-us": { "role": { "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssued", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r8" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r352" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "ovtz_ConsultingFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ConsultingFeesMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details" ], "lang": { "en-us": { "role": { "label": "Consulting Fees [Member]", "documentation": "Represents consulting fees paid." } } }, "auth_ref": [] }, "ovtz_SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved": { "xbrltype": "percentItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "ovtz_SharebasedCompensationArrangementPercentOfIssuedAndOutstandingCommonSharesReserved", "terseLabel": "Share-based Compensation Arrangement, Percent of Issued and Outstanding Common Shares Reserved", "documentation": "The percent of issued and outstanding common shares reserved in a share-based compensation." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r352" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "lang": { "en-us": { "role": { "label": "Ownership interest", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r352" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "ovtz_FilingAndRegulatoryFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "FilingAndRegulatoryFee", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "lang": { "en-us": { "role": { "label": "Filing and regulatory fees", "documentation": "Expenditures for filing and regulatory." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r48", "r63", "r260", "r268", "r269", "r274", "r287", "r341" ] }, "ovtz_ScheduleOfWarrantsOrRightTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ScheduleOfWarrantsOrRightTableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrants or Right [Table Text Block]", "documentation": "Tabular disclosure of an entity's warrants or rights." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "ovtz_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "terseLabel": "Granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r177" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r56" ] }, "ovtz_RangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "RangeFourMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Range Four [Member]", "documentation": "Represents range four." } } }, "auth_ref": [] }, "ovtz_OperatingLeasesMonthlyRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "OperatingLeasesMonthlyRentExpense", "crdr": "debit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "ovtz_OperatingLeasesMonthlyRentExpense", "terseLabel": "Operating Leases, Monthly Rent Expense", "documentation": "Amount of monthly rent expense incurred under the operating lease." } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Effect of foreign currency translation", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details" ], "lang": { "en-us": { "role": { "label": "Expired, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r178" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r169", "r238", "r239", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r281", "r282", "r283", "r284", "r285", "r303", "r305", "r333", "r404" ] }, "ovtz_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ovtz_ClassOfWarrantOrRightExpiredDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ClassOfWarrantOrRightExpiredDuringPeriod", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "ovtz_ClassOfWarrantOrRightExpiredDuringPeriod", "negatedLabel": "Expired (in shares)", "documentation": "The number of warrants or rights expired during period." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r56", "r93" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r97", "r98", "r238", "r239", "r240", "r241", "r281", "r282", "r283", "r284", "r285", "r303", "r305", "r333" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ovtz_ClassOfWarrantOrRightExpiredDuringPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ClassOfWarrantOrRightExpiredDuringPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Expired (in dollars per share)", "documentation": "Per share or per unit weighted average exercise price of warrants or rights expired during the period." } } }, "auth_ref": [] }, "ovtz_RangeFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "RangeFiveMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Range Five [Member]", "documentation": "Represents range five." } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "ovtz_CommonStockSharesHeldInEscrow": { "xbrltype": "sharesItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "CommonStockSharesHeldInEscrow", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual" ], "lang": { "en-us": { "role": { "label": "ovtz_CommonStockSharesHeldInEscrow", "terseLabel": "Common Stock, Shares Held in Escrow (in shares)", "documentation": "Number of common stock held in escrow." } } }, "auth_ref": [] }, "ovtz_RangeSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "RangeSixMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Range Six [Member]", "documentation": "Represents the range six." } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r364", "r365" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Currency translation differences", "label": "Currency translation differences", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r52", "r224", "r225", "r226" ] }, "ovtz_RangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "RangeThreeMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Range Three [Member]", "documentation": "Represents range three." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "ovtz_ConsultingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ConsultingExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Consulting (Note 11)", "documentation": "The aggregate costs incurred for consultation." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r61" ] }, "ovtz_ResearchAndDevelopmentExpenseBusinessDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ResearchAndDevelopmentExpenseBusinessDevelopment", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details" ], "lang": { "en-us": { "role": { "label": "Business development", "documentation": "Research and development expense during the period related to business development." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 }, "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details" ], "lang": { "en-us": { "role": { "label": "Research and development (Note 10)", "totalLabel": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r41", "r198", "r407" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in accounts payable and accrued liabilities \u2013 related parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r56", "r57", "r58" ] }, "ovtz_ComplytrustIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ComplytrustIncMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details" ], "lang": { "en-us": { "role": { "label": "ComplyTrust Inc. [Member]", "documentation": "Represents ComplyTrust Inc." } } }, "auth_ref": [] }, "ovtz_RangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "RangeTwoMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Range Two [Member]", "documentation": "Represents range two." } } }, "auth_ref": [] }, "ovtz_ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ScheduleOfSellingGeneralAndAdministrativeExpensesTableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Selling, General and Administrative Expenses [Table Text Block]", "documentation": "Tabular disclosure of selling, general and administrative expenses." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "terseLabel": "Prepaid expenses and other current assets (Note 4)", "totalLabel": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r358" ] }, "ovtz_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Research and Development Expenses [Table Text Block]", "documentation": "Tabular disclosure of research and development expenses." } } }, "auth_ref": [] }, "ovtz_CommitmentToIssueSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "CommitmentToIssueSharesMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "Commitment to Issue Shares [Member]", "documentation": "Represents commitment to issue shares." } } }, "auth_ref": [] }, "ovtz_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "label": "ovtz_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Warrants outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Warrants outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price of class of warrant or right outstanding." } } }, "auth_ref": [] }, "ovtz_ResearchAndDevelopmentExpensePayroll": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ResearchAndDevelopmentExpensePayroll", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details" ], "lang": { "en-us": { "role": { "label": "Payroll", "documentation": "Research and development expense during the period related to payroll." } } }, "auth_ref": [] }, "ovtz_ResearchAndDevelopmentExpenseProjectManagement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ResearchAndDevelopmentExpenseProjectManagement", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details": { "parentTag": "us-gaap_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details" ], "lang": { "en-us": { "role": { "label": "Project management", "documentation": "Research and development expense during the period related to project management." } } }, "auth_ref": [] }, "ovtz_ClassOfWarrantOrRightRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ClassOfWarrantOrRightRemainingContractualTerm", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Remaining contractual life (Year)", "label": "ovtz_ClassOfWarrantOrRightRemainingContractualTerm", "documentation": "Remaining contractual term of class of warrant or right." } } }, "auth_ref": [] }, "ovtz_ClassOfWarrantOrRightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ClassOfWarrantOrRightTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Text Block]", "documentation": "The entire disclosure for warrant or right." } } }, "auth_ref": [] }, "ovtz_RollingStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "RollingStockOptionPlanMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Rolling Stock Option Plan [Member]", "documentation": "Related to the Rolling Stock Option Plan." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash paid during the period for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r90", "r91", "r92" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostsAndExpenses", "negatedTotalLabel": "Loss from operations", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r54" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r189", "r190", "r191", "r278", "r366", "r367", "r368", "r400", "r412" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r169", "r238", "r239", "r281", "r282", "r283", "r284", "r285", "r303", "r305", "r333" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r79", "r141", "r142", "r336" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r238", "r239", "r404" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r31" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r37", "r337" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-cash-flows-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-research-and-development-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-10-research-and-development-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-14-segmented-information", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern", "http://www.oculusvisiontech.com/20230930/role/statement-note-2-going-concern-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-summary-of-subsidiary-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-summary-of-accounts-payable-and-accrued-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-5-accounts-payable-and-accrued-expenses-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock", "http://www.oculusvisiontech.com/20230930/role/statement-note-6-common-stock-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-changes-in-options-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-of-options-outstanding-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-tables", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details", "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-tables", "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r99", "r100", "r101", "r120", "r243", "r272", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r307", "r308", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r326", "r345" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r170", "r172", "r186", "r187", "r188", "r340" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r373" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-1-basis-of-presentation-and-business" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r43", "r65", "r270", "r271" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details": { "parentTag": "us-gaap_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-9-selling-general-and-administrative-selling-general-and-administrative-expenses-details" ], "lang": { "en-us": { "role": { "label": "Professional fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r350", "r410", "r411" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-details-textual", "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties-related-party-expenses-details" ], "lang": { "en-us": { "role": { "label": "Related party transactions", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r39", "r238" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-", "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PreferredStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNoParValue", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, no par value (in dollars per share)", "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r45", "r372" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited", "http://www.oculusvisiontech.com/20230930/role/statement-note-12-financial-instruments-and-risks-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "terseLabel": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r15", "r76", "r96", "r138", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r209", "r210", "r211", "r222", "r341", "r370", "r405", "r406" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r16", "r74", "r85", "r86", "r87", "r99", "r100", "r101", "r103", "r109", "r111", "r120", "r139", "r140", "r168", "r189", "r190", "r191", "r206", "r207", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r265", "r266", "r267", "r278", "r326" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options", "http://www.oculusvisiontech.com/20230930/role/statement-note-7-stock-options-details-textual" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r74", "r99", "r100", "r101", "r103", "r109", "r111", "r139", "r140", "r189", "r190", "r191", "r206", "r207", "r212", "r214", "r215", "r217", "r219", "r265", "r267", "r278", "r412" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r118" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r74", "r85", "r86", "r87", "r99", "r100", "r101", "r103", "r109", "r111", "r120", "r139", "r140", "r168", "r189", "r190", "r191", "r206", "r207", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r227", "r228", "r229", "r230", "r231", "r232", "r234", "r265", "r266", "r267", "r278", "r326" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r356" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-11-related-parties" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r235", "r236", "r237", "r239", "r242", "r275", "r276", "r277", "r309", "r310", "r311", "r330", "r332" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r223" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases", "http://www.oculusvisiontech.com/20230930/role/statement-note-13-operating-leases-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r356" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Expenses:" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-condensed-interim-consolidated-statements-of-stockholders-equity-deficiency-unaudited" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r6", "r17", "r213", "r216", "r234", "r265", "r266", "r360", "r361", "r362", "r366", "r367", "r368" ] }, "ovtz_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.oculusvisiontech.com/20230930", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.oculusvisiontech.com/20230930/role/statement-note-8-warrants-schedule-of-warrants-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of warrants exercisable (in shares)", "label": "ovtz_ClassOfWarrantOrRightExercisable", "documentation": "Number of warrants or rights exercisable." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a-c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "985", "SubTopic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//985-730/tableOfContent" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-12" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r352": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r354": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 65 0001437749-23-031136-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-031136-xbrl.zip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�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